Podcasts about Iga

Privileged Access Management has outgrown the vault. In this episode, Matthias sits down with lead analyst Alejandro Leal, author of KuppingerCole's newly released PAM Leadership Compass, to explore how the definition of privilege itself has changed, what NHIs and agentic AI mean for PAM, and why deployment sovereignty is now a boardroom conversation. Key Topics: ✅ How the definition of "privilege" has shifted from admin accounts to dynamic runtime identity capabilities✅ PAM convergence with IGA, CIEM, ITDR, SIEM, and SOAR — the end of the standalone PAM product✅ Non-Human Identities (NHIs) and agentic AI: the silent accumulation of machine privilege✅ Just-in-time access: the gap between concept and operational reality✅ Deployment sovereignty: who controls the keys to the kingdom — SaaS, on-prem, or hybrid?✅ AI and ML in PAM: separating genuine innovation from marketing inflation "Most enterprises can tell you the number of employees they have — very few can tell you the number of machine identities." If that sounds familiar, this episode is for you.

Privileged Access Management has outgrown the vault. In this episode, Matthias sits down with lead analyst Alejandro Leal, author of KuppingerCole's newly released PAM Leadership Compass, to explore how the definition of privilege itself has changed, what NHIs and agentic AI mean for PAM, and why deployment sovereignty is now a boardroom conversation. Key Topics: ✅ How the definition of "privilege" has shifted from admin accounts to dynamic runtime identity capabilities✅ PAM convergence with IGA, CIEM, ITDR, SIEM, and SOAR — the end of the standalone PAM product✅ Non-Human Identities (NHIs) and agentic AI: the silent accumulation of machine privilege✅ Just-in-time access: the gap between concept and operational reality✅ Deployment sovereignty: who controls the keys to the kingdom — SaaS, on-prem, or hybrid?✅ AI and ML in PAM: separating genuine innovation from marketing inflation "Most enterprises can tell you the number of employees they have — very few can tell you the number of machine identities." If that sounds familiar, this episode is for you.

"Iga raamat hakkab oma elu elama, igal raamatul on oma saatus," ütleb kirjanik, kirjastaja ja käsikirjade toimetaja Epp Petrone, kelle kirjastuse Minu-sari on jõudnud kahesajanda raamatuni.

Martín Letelier vuelve de París con polerita oficial, raqueta, mochila llena de stickers y una experiencia para contar de pe a pa. Felipe conduce y se transforma en oyente privilegiado mientras Martín relata su primer Grand Slam: el "Disneyland del tenis", el ballotage de Roland Garros, las entradas de 34 euros (sí, leíste bien), el ground pass que te deja entrar a Philippe Chatrier si no está lleno, la estatua de Nadal en la entrada con las 14 finales grabadas, y la batalla épica de gritos entre la dupla francesa y los pocos chilenos en una cancha auxiliar viendo a Tabilo jugar dobles.Después hablamos de tenis. La amarga derrota de Tabilo contra Félix en octavos, la baja providencial de Vacherot que abrió el camino, y la polémica con Séptimo Game cuestionando que Tabilo jugara dobles el día anterior (Martín le rebate punto por punto). La caída de Sinner con la teoría caballerosa de Martín, "la final del mundo" Djokovic vs Fonseca y la confianza que se construye al ganarle a un grande, el regreso anunciado de Serena Williams a los 46, las notas de Caterina con Sabalenka como favorita clara, Iga eliminada y la promesa de Marta Kostiuk.Y la evaluación de los cuartos de final pronosticados: la sección 1 fue un desastre total (¿alguien tenía a Berrettini vs Arnaldi?), la sección 2 cumplió con Félix vs Cobolli, en la sección 3 nos jugamos a Fonseca vs Mensik y en la sección 4 acertamos con Zverev vs Jodar (con la triste vuelta a la realidad del español). Cierre con la pregunta del millón: ¿quién gana este Roland Garros tan abierto?Síguenos en Instagram @lucklosers_podcast Twitter @LuckyLoserscast  @luckyloserstenis Youtube https://www.youtube.com/@luckyloserspodcast8246

Jeff and Jim recap their week at KuppingerCole's EIC 2026 in Berlin, covering standout keynotes, hallway conversations, and sessions on securing AI agents, CIAM, and AI versus nuclear regulation. They announce a giveaway of Eve Maler's signed copy of Mastering Digital Identity for YouTube commenters by June 12th. The episode also features live footage and a full interview with Espen Bago, founder of Identibeer, recorded at the Berlin event. Jeff, Jim, and Espen discuss the rapid global growth of the Identibeer community, terminology challenges around NHI and IAM concepts, the gap between conference talk and real client needs, and why the industry keeps bypassing foundational data work in the rush toward AI and agentic identity.Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.com00:00:10 Welcome and EIC 2026 Setup00:03:57 Eve Maler Book Giveaway Details00:05:00 Conference Highlights: Keynotes and Hallway Con00:06:07 Elizabeth Garber's Standing Ovation Keynote00:07:02 Brazil Invitation and Securing AI Agents00:09:10 Nuclear Regulation vs. AI Regulation00:11:07 Upcoming EIC Episode Preview00:14:16 Identibeer Berlin Live Event00:14:29 Interview with Espen Bago Begins00:15:14 Identibeer Growth and Global Expansion00:17:23 The Identibeer Name Debate00:23:26 Data Quality Gaps in NHI and IAM00:26:31 Who Owns IAM Terminology?00:34:20 Conference Talk vs. Client Reality00:40:52 The HR-IAM Gap Nobody Talks About00:43:17 Fundamentals: The Karate Kid AnalogyKeywords: EIC 2026, European Identity Conference, Identibeer, Espen Bago, Eve Maler, Elizabeth Garber, Mastering Digital Identity, Berlin, Identiverse, NHI, non-human identities, IAM fundamentals, AI regulation, agentic identity, IGA, PAM, CIAM, IDPro, identity community, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald

Send us Fan MailWeek 1 of Roland Garros delivered pure unhinged energy, and Resh and Stef were SCREAMING — recording live together in San Francisco for the first time in two years. The biggest WTA story? Clayomi. Naomi Osaka walked out in a Germanier x Nike couture collab ("I look like the Eiffel Tower at night"), made it to the fourth round for the first time in her Roland Garros career, and co-hosted an invite-only Black Party at Soho House Paris with Taylor Townsend. She's serving on and off the court, and the haters (hi, Laura Siegemund) can sit down. Meanwhile, Resh's pick Coco Gauff — the defending champion — lost a gut-punch third-rounder to Potapova, Hailey Baptiste went down with ACL and meniscus injuries at her career peak, and Victoria Mboko broke our hearts in a three-setter against Madison Keys. Also: it sounds like Serena Williams may be coming back to tennis as soon as next week. This is not a drill.On the men's side, the Chaos Slam claimed its biggest victim when top seed Jannik Sinner — up two sets and 5-1 — melted in the sun and lost to the less known Cerundolo in five. The sun remains undefeated. Bright spots: 21-year-old Stanford data science student Nishesh Basavareddy upset 7-seed Taylor Fritz with cold-blooded drop shots, 17-year-old Moïse Kwame became the youngest player to win a Roland Garros match since 1991 (his prize money is locked in a bank until his 18th birthday, because France), and João Fonseca closed out a five-set win over Djokovic on three straight aces like it was nothing.We also need to talk about ATP player Adolfo Daniel Vallejo, who blamed his loss on female umpire Ana Carvalho — a silver badge professional and one of the best in the world — claiming she lacked the "strength" to handle the crowd. Roland Garros fined him and issued a statement. We revisit the Hurkacz 2024 incident, the Fognini 2017 incident, and note that Roland Garros's allyship would land harder if women's matches were ever scheduled in prime time. Heading into week 2: Sabalenka and Iga are the top contenders (despite the hosts' predictions), the Ukrainian sweep is still mathematically alive, and Naomi faces Sabalenka in what is absolutely must-watch Monday tennis.Support the showInstagram : Out_Wide_PodcastJingle : https://www.nelaruizcomposer.com/Logo: https://www.instagram.com/crayonspaghetti/

How to Interpret Paediatric Microbiome Testing Correctly (and What Most Parents Aren't Told)This week on the Natural Super Kids Podcast, we're talking about one of the biggest issues we are seeing in children's health right now, the misinterpretation of paediatric microbiome testing.With more families turning to gut microbiome testing to understand eczema, allergies, digestive symptoms, immune issues, and overall health, it's becoming increasingly important for parents to understand that children's microbiome results cannot be interpreted the same way as adults'.We share key insights from a recent paediatric microbiome mentoring program with Dr Brad Leech. During this, Dr Brad explained the common mistakes that can lead to unnecessary supplementation, restrictive diets, and incorrect “leaky gut” diagnoses in children, which we wanted to share with you today.In this episode, we explore:Why most microbiome tests for kids use adult reference ranges that may not apply to childrenThe truth about zonulin, secretory IgA, and microbiome diversity scores in kids under 12Why a child's age, diet, breastfeeding history, and immune development matter when interpreting resultsHow the right practitioner and the right testing technology can make a huge difference in getting useful, accurate information

Tänane külaline on Liis, on naine, kes ütleb enda kohta, et ta on “täiesti tavaline Eesti inimene” aga tema teekond ei ole olnud seda kindlasti. Tema elu ei ole kulgenud sirgjooneliselt. Vastupidi, see on olnud täis otsinguid, murdekohti ja hetki, kus kogu senine maailmapilt on kokku kukkunud. Seljakotirännak Austraalias, kus ta koges hülgamist. Vipassana meditatsioon Tais, kus ta esimest korda tundis puhast armastust inimeste vastu. Suvi telgiga Londoni parkides. Otsingud Indias. Ja vahepeal täielik lahtilaskmine, loobumine harjumustest, asjadest, identiteedist. Tema teekond ei ole olnud vastuste leidmine, vaid küsimuste sügavamaks muutumine. Täna uurib Liis elu läbi vaimsete praktikate, filosoofia ja isikliku kogemuse, otsides, mis on päriselt tõde, mitte see, mida meile on õpetatud uskuma. Ja võib-olla kõige ausam küsimus, mida ta endalt küsib on: “Kas ma olen midagi leidnud, või olen ma alles teel?” --- SHOWNOTES — TUGEVAD MÕTTED "Hirmsast unenäost on suurem motivatsioon üles ärgata kui heast unenäost." "Keegi ei küsinud — ja sellepärast ma ei rääkinud." "Kogu aeg oli tunne, et räägin välja perekonna saladuse." "Esimesed 20 aastat arvasin, et elu ongi nii — ja positiivselt mõtlejad pole lihtsalt veel piisavalt kogenud." "Funktsioon ei olnud see, et elu oleks ilus, vaid et järgmise päevani vastu pidada." "Ma armastan sind sellepärast, et sa oled olemas — mitte sellepärast, mida sa teed." "Guru on nagu lennuk, mis lendab su kohal ja ootab, et sul oleks piisavalt vaba ruumi, et maanduda." "Mõtted viitavad kogemusele, aga nad ei ole kogemus ise." "Maailm on loodud inimesele — ja see on müüt, milles me kõik elame." "Kui sa oled oma mõttes, oled sa alati ühe mõtte kaugusel reaalsusest." "Mul on alati valida — kas olla solvunud või jätkata tingimuseta armastuse andmist." "Valu on olnud minu parim nõelravi." "Austraalia õpetas mulle, et elu ei pea olema raske." "Vastutuse võtmine enda eest on see, mis tegelikult elu muudab — mitte aeg." "Ma ei tea, kus ma oleksin, kui ma poleks endaga tegelenud. Kas mind oleks üldse." "Nothing excites me — ja see ei ole probleem, see on shift." "Teises riigis hakkad aru saama, mis sinu enda kultuuris on lihtsalt harjumus, mitte tõde." "Iga tehnika teeb oma töö ära — ära jää sellesse kinni." "Ellujäämine ei ole saavutus — see on lähtepunkt." "Inimkontakt on põhiline — see on natuke ära kadunud, aga selle jaoks me siin oleme." ---

Jeff and Jim are back with the May 2026 mailbag, answering listener questions from Amsterdam, Mumbai, Austin, and Berlin. Topics include navigating IAM vendor acquisitions, defending against AI deepfakes in remote onboarding, governing contractor and third-party identities, fixing the leaver process in IGA, and tackling a decade of IAM technical debt. The episode closes with unpopular industry opinions: why RFPs are procurement theater, why rip and replace should be normalized, and why one-throat-to-choke vendor thinking usually backfires.IDPro new member discount: https://idpro.org/idac/Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comCHAPTER TIMESTAMPS00:00 Intro and SNL nostalgia03:25 AI model roundup: ChatGPT, Claude, Gemini, and usage limits10:16 Identiverse 2026 and IDPro member discount14:53 Q1: Navigating vendor acquisitions (Isabelle, Amsterdam)24:00 Q2: AI deepfakes in identity verification (Rajan, Mumbai)32:32 Q3: Contractor and third-party identity governance (Caleb, Austin)43:00 Q4: The leaver process and IGA scope gaps (Anonymous)51:10 Q5: Tackling IAM technical debt (Tomas, Berlin)57:00 Normalizing rip and replace01:01:00 RFPs, one throat to choke, and other hot takes01:08:00 Wrap-upKEYWORDSIAM, identity governance, IGA, vendor consolidation, acquisitions, deepfakes, identity verification, contractor management, non-employee identity, technical debt, rip and replace, RFP, joiner mover leaver, leaver process, Identiverse 2026, IDPro, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald

As The Body Serve heads to Paris for the first time, here's our preview of the 2026 edition of Roland Garros, where Jannik Sinner seeks to make more history and a number of top women find themselves in position to snatch. As usual, we take you through both draws: a surprisingly balanced women's draw (except for Iga -- sorry, girl) and a men's draw with not much intrigue, at least on the surface. The players associated with Project Red Eye have staged a work-to-rule labour action, refusing rightsholder interviews and committing only 15 minutes to pre-tournament media activities. Also, the federal judge in the PTPA case couldn't order Wimbledon and the French to give up those coveted press credentials. I guess they're stuck buying tickets like everybody else!   1:05 Qualifiers: Sloane through; Plishy & Greg are not :(  4:45 This week: Casper, rest! 7:20 Women's draw  20:20 Men's draw  39:55 PTPA credentials drama: judge says it's petty but what can I do, babes 42:50 Players stage a labour action! 49:05 Stevie Wonder, randomly

Jimmy and Brett are back after a short hiatus to preview Roland Garros 2026. Can anyone stop Jannik Sinner from completing the career grand slam? Can Djoker win major #25? Will someone new make a run to the finals? The women's draw is much more wide open then the men. Can Coco repeat? Will Sabby get revenge for last year? Will we get another Iga vs Ostapenko matchup? So many great storylines on the women's side. Jimmy answers some of your questions on a brand new Advantage Connors podcast! Follow us on - Twitter - @AdvConnors @JimmyConnors @Brett_Connors Instagram - @AdvConnors @Bretterz @GolddoodIsabella Facebook - Jimmy Connors official Facebook page Leave your questions/topics/or links to stories you want us to talk about next week on Jimmy's official Facebook page. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hydrogen water—breakthrough or scam? Osteoporosis fixes; Nattokinase for cardiovascular prevention; Why vitamin D helps a subset of diabetics; When oral vitamin D doesn't work, sublingual D may normalize blood levels; Vitamin D found beneficial for colitis; Why fructose stokes food cravings; Flawed fluoridation study claims no IQ harms to kids.

W dzisiejszym magazynie sportowym: Iga Świątek w półfinale turnieju w Rzymie; Lech Poznań mistrzem na kolejkę przed zakończeniem rozgrywek piłkarskiej ekstraklasy; zwycięstwo Polaka w wyścigu Indianapolis...

In the final episode, Pranav Garimella explores glomerular and cystic kidney diseases, including IgA nephropathy and autosomal dominant polycystic kidney disease. Discover how personalised medicine, biomarkers, and earlier diagnosis are shaping the future of care in these complex conditions. Timestamps: 01:11 – Current treatment for IgA nephropathy 02:24 – SGLT2 inhibitors 03:38 – Cystic kidney disease diagnosis

4x Grand Slam champion Kim Clijsters and tennis reporter Blair Henley are joined by WTA pro and model Carson Branstine to discuss the realities of life on tour outside the top 100. Carson, currently recovering from a torn labrum, opens up about funding her career without a coach or physio, her viral TikTok calling out player welfare failures, and how she balances tennis with modeling and a new finance venture. Kim adds perspective from her time on the WTA board and her own battles with the tour's injury fine system.  Kim and Blair also break down a busy week in Rome: Sorana Cirstea beating Sabalenka at 36 years old and reconsidering her retirement and Coco Gauff's admission of off-court struggles. They also weigh in on Project Red Eye, the player-led push for greater Grand Slam revenue sharing, and the story of Ukrainian player Oleksandra Oliynykova, who is using her platform to raise funds for the Ukrainian military. Kim closes with a tactical breakdown of Iga Swiatek's backhand slice, explaining why it has become one of the most effective weapons on tour heading into Roland Garros. Welcome to Love All! If you want to hang out with us behind the scenes follow us on all of our socials: https://www.instagram.com/loveallpodcast/ https://www.tiktok.com/@loveallpodcast  https://x.com/loveallpodcast  ' Kim's Recs Mouth Tape: https://zippit.nl/en/products/mouth-tape?shpxid=6de1bfcf-6ccc-45df-81f6-c3866e134212  Powder SPF: https://www.nomige.com/en/pages/leeray?srsltid=AfmBOoqztTF81pHzn42YLvMfTi3r66QSCxEpBvuZY26Q-9wmEN9j1Og3  Blair's Rec SPF Setting Spray https://www.onesizebeauty.com/products/on-til-dawn-mattifying-sunscreen-makeup-setting-spray-spf-28-full?srsltid=AfmBOorYde4DM29IipIoN4yJZqGzsR5_8PeRY3XihUDevWe_f1odVst6&variant=45363114574023  ⏰ TIMESTAMPS:  0:00: Welcome to Love All 1:09: Carson Branstine joins Love All 3:02: Carson on Kim Clijsters as her idol & inspiration to play tennis 5:28: Injury update 8:29: Carson's life off court 11:28: Carson's viral TikTok: The realities of life on the WTA tour 13:54: Reaction to the TikTok 18:51: Kim & Carson on player costs, prize money & the financial grind of pro tennis 25:02: Can you have quality of life and compete at the highest level in tennis? 35:22: Henley's Headlines: Rome Open update & Sorana Cîrstea's retirement year story 44:13: Aryna Sabalenka's form heading into Roland Garros 45:55: Coco Gauff's emotional struggles  51:03: Oleksandra Oliynikova: Using her platform to support Ukraine & challenging the WTA 59:09: Kim-formation: Iga Świątek's renewed joy with coach Francisco Roig 1:01:40: Iga's backhand tactics against Osaka 1:04:16: Francisco Roig ruptures his Achilles at practice & returns immediately 1:07:15: Holger Rune skips Roland Garros to protect his Achilles recovery 1:08:42: Rec Room: Mouth tape, SPF setting spray & brush-on sunscreen  1:14:07: Closing thoughts  Learn more about your ad choices. Visit megaphone.fm/adchoices

Functional Diagnostic Nutrition: Using Saliva Testing, Food Sensitivity Labs, and Lifestyle to Find Root Causes: Reed Davis, Board Certified Holistic Health Practitioner (HHP) and Certified Nutritional Therapist (CNT), is founder of Functional Diagnostic Nutrition (FDN). He discusses using functional testing alongside conventional care to uncover “dysfunction” when standard labs appear normal. Davis describes assessing adrenal and metabolic stress via saliva testing for circadian cortisol patterns, cortisol-DHEA balance, sex hormones, secretory IgA, and melatonin, emphasizing clinical correlation and individualized “studies of one.” He outlines an approach targeting multiple “healing opportunities” (H-I-D-D-E-N: hormones, immune, digestion, detoxification, energy, nervous system) and applying D-R-E-S-S (diet, rest, exercise, stress reduction, supplementation) rather than relying on supplements alone. A case example links chronic hives, medication-related weight gain, and food triggers identified through additional testing, including the Mediator Release Test. The discussion also covers stress-driven gut dysbiosis, digestion decline, and EFT tapping for stress-related symptoms, and notes FDN practitioners can be found via FDNtraining.com/medicine.

Luc Dupont analyse les plus récentes données de Comscore sur les usages numériques au Canada, qui montrent une hausse généralisée de l'utilisation d'Internet sur téléphone intelligent, tablette et ordinateur. La vidéo domine désormais la consommation d'actualité, notamment sur YouTube, tandis que l'audio progresse fortement avec Spotify. L'étude révèle aussi des comportements plus marqués selon les générations, avec TikTok et Snapchat chez les jeunes, alors que les plus âgés privilégient Facebook, Google Maps ou les services météo. Du côté du commerce en ligne, Amazon domine largement, suivi notamment de Temu, Walmart et des acteurs canadiens comme Canadian Tire et IGA. Enfin, l'intelligence artificielle commence déjà à redéfinir les usages numériques, avec OpenAI et son outil ChatGPT qui s'imposent comme référence auprès du grand public.

Odcinek z wideo na dostępnym na YouTube. Iga na urlopie, więc zastępuje ją godnie Adam Piechota – człowiek wykształcony i kształcący. W tym odcinku wszyscy jesteśmy z młodzieżą, ale ze starszą młodzieżą, taką co to tęsknie wspomina X360, lata 90. i retrofuturyzm spod znaku Cyberpunka 2020. Dlatego w CJG przedstawiamy wam: Z kolei w sekcji […]

W dzisiejszym magazynie sportowym: Iga Świątek jedyną Polką w trzeciej rundzie w Rzymie; zacięta rywalizacja w końcówce polskiej ekstraklasy piłkarskiej; czwarte miejsce reprezentacji Polski w hokeju na lodzie na mistrzostwach świata w Sosnowcu.

Nick is back from a birthday recharge in Wales and we're getting into Rome. Sinner is playing in all-black Gucci and closing in on the Career Masters at 24. Arthur Fils, Ben Shelton, Fonseca, and FAA are all out or struggling three weeks before Roland Garros. Sabalenka looks beatable for the first time in a while, Iga might be back, and the WTA field has gotten very wide open very fast. Plus housekeeping on the last day of spring merch pre-orders, our McCarran Park screening dates for Roland Garros and Wimbledon, an Off Season check-in, and our Players of the Fortnight.Links: Merch: https://www.groundpasspodcast.com/shop Mattia's Meet the Player interview: https://youtu.be/5fEWXVYtYRI?si=6Lrh1hgBAdAC541x Hailey Baptiste Tee: https://www.groundpasspodcast.com/shop/p/off-season-tour-tee-hailey-baptiste-limited-editionChapters:00:00 Welcome and Housekeeping05:32 Two Week Masters are OUT10:03 The State of the ATP Tour17:58 Novak Djokovic's Return and Future Prospects21:11 Janik Sinner's Dominance and Historical Context25:53 The WTA Landscape: Surprises and Uncertainties31:30 Retirement Announcements and Their Impact on Performance34:06 Paolini out of the top 1039:31 TNT is back for Roland Garros Coverage in the US & UK44:50 Catching up with the Off Season49:16 What's coming up next on tour52:20 Highlighting Players of the Fortnight57:11 Outro

IgA nephropathy and IgA vasculitis remain complex and evolving areas in nephrology care. In this episode, experts discuss key insights from the KDIGO guidelines and KDOQI commentary published in AJKD, focusing on updated approaches to risk stratification, disease progression, and treatment decision making. The conversation highlights the role of supportive care, immunosuppressive therapy considerations, and emerging therapeutic options, while addressing variability in clinical practice and patient management challenges. This episode provides practical, evidence based perspectives to help clinicians navigate the nuances of IgAN and IgAV care and apply guideline recommendations in real world settings. Please view the AJKD article here.

Send me a text! I'd LOVE to hear your feedback on this episode!You've probably been told your appendix and tonsils are basically optional. I don't buy that — and the research backs me up.In this episode I break down the full story on two of the most dismissed organs in the body. What they actually do, why they matter more than you've been told, what drives removal, and what can shift afterward — plus how to support yourself whether you still have them or not.Your appendix is an active microbiome reservoir that helps reseed your gut after illness, infection, or antibiotics, and plays a direct role in IgA immune regulation. Your tonsils are your immune system's first line of defense — tied to your oral microbiome, lymphatic drainage, airway mechanics, and vagus nerve tone. These are not evolutionary leftovers. They are functional, living parts of systems your body depends on daily.I cover what actually drives appendicitis and tonsil failure, the connection to dysbiosis and chronic inflammation, and what people notice after removal — gut reactivity, anxiety, shifted gut-brain signaling, and immune changes. I also walk through the practical tools that support your body on both sides — fibre, prebiotics, polyphenols, gut barrier support, warm salt water gargling, nasal breathing, tongue posture, anti-inflammatory nutrition, hydration, and nervous system regulation.I also explore the somatic and energetic layer — safety and intuition with the appendix, and voice, truth, and boundaries with the tonsils. Science and soul, together.This is Part 2 of 2. Part 1 covers the gallbladder and uterus — two more organs dismissed as optional that your body would strongly disagree with.  Listen to Part 1 here:  https://podcasts.apple.com/ca/podcaJoin here:  Sandy K Inner Circle Join me here:  Sandy K Inner CircleSupport the showJoin The Sandy K Inner Circle -- my private women-only subscription community where we go deeper than the podcast ever could.Every month you get:A live Q&A with Sandy on ZoomAn exclusive podcast episode nobody else hearsA practical curated downloadAccess to our private women-only Facebook community for wide open discussions on all topicsNo agendas. No noise. No bias. No trendy health advice from those who pay for their platforms. No medical advice. Real conversations you will not find anywhere else.Founding member spots are limited at $47 CAD/month.Join us here: sandykruse.substack.comFor women only. By invitation.Instagram:  https://www.instagram.com/sandyknutrition/Facebook Page:  https://www.facebook.com/sandyknutritionTikTok:  https://www.tiktok.com/@sandyknutritionYouTube: https://www.youtube.com/channel/UCIh48ov-SgbSUXsVeLL2qAgRumble:  https://rumble.com/c/c-5461001Linkedin:  ...

Recorded live as part of the Identity Management Day 2026 streaming program, Jeff and Jim mark their fifth IMD episode. Introduced by Jeff Reich from the Identity Defined Security Alliance, they reflect on how the IAM industry has evolved since their first IMD episode in 2021 and grade overall progress a C. Topics include what has genuinely improved (passkeys, MFA adoption, broader awareness), what hasn't (compliance fatigue, security theater, persistent credential theft), the exploding challenge of non-human identity governance, whether AI will eventually need to certify other AI, and how AI-powered phishing and deep fakes are raising the bar for identity verification. The episode wraps with chat-submitted IAM bumper stickers.Identity Management Day 2026: https://www.idsalliance.org/event/identity-management-day-2026/Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comCHAPTERS0:00 - Jeff Reich intro from the IMD stream2:00 - Identity Management Day 2026 kicks off3:30 - Five years of IMD: a look back at episode 887:00 - Does IMD move the needle?9:30 - Who is Identity Management Day actually for?12:00 - What has improved in IAM over five years16:00 - What hasn't improved: compliance fatigue and security theater18:30 - Grading the IAM industry21:00 - NHI governance: visibility and accountability26:00 - Can AI certify AI? Agentic identity governance29:00 - AI-powered phishing and the evolving threat landscape32:00 - Deep fakes and the identity verification challenge36:00 - Lighter note: IAM bumper stickersKEYWORDSidentity management day, identity management day 2026, NHI, non-human identity, agentic AI, phishing, deep fakes, IGA, passkeys, MFA, IAM, identity governance, access management, cybersecurity, credential theft, security awareness, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald

#317 I'm a degree-qualified naturopath with over 20 years of clinical experience, with a primary focus on complex gut health conditions — and in this video, I'm doing something I've never done before. I'm turning the lens on myself. I recently got my own gut microbiome tested, and I want to walk you through every single result. I didn't get tested because I had gut symptoms — my bowels are actually moving beautifully. I got tested because I'd been dealing with over a year of persistent rosacea and wanted to know: could what's happening in my gut be connected to what's showing up on my skin? I also wanted to show you exactly what this test looks like when it's interpreted by someone who does this for a living. We cover every section of the report — the pathogen panel, the diagnostic GI markers, microbiome diversity and richness, short-chain fatty acids, TMA, emerging metabolites, the species table, and more. I also share the result that was flagged as severely abnormal — and why, in context, it almost certainly isn't. This is what it looks like to use real data to motivate real change — not because something has gone terribly wrong, but because catching the trajectory early is the whole point. What we cover What makes shotgun metagenomics different from other stool tests The targeted pathogen panel — what it tests for and what my results showed Pancreatic elastase — the result that flagged severely low, and why context changes everything Lactoferrin, calprotectin, zonulin, secretory IgA, and faecal occult blood Microbial diversity and richness — what we're aiming for and why it matters Butyrate, acetate, propionate, and TMA — what they mean and how diet influences them Prevotella copri — nuanced, misunderstood, and more common in traditional diets than you'd think Emerging markers, including GABA, and why we need to hold them lightly Human DNA elevation — and why collection context explains it My action steps and why seeing this data now motivates me to act I'm Lynda Griparic, a degree-qualified naturopath with extensive experience in complex gut health conditions, including SIBO, IMO, and chronic constipation. Book a consultation or shop BetterMe Tea at lyndagriparic.com This content is for educational purposes only and is not intended as medical advice. Please consult with your healthcare provider before making any changes to your health routine.

Whether it was bad shrimp or a virus, the outcome – or the output, rather – was the same. Week one of Madrid was rocked by player illness and withdrawals, with Iga retiring for only the second time in her career and Coco getting sick on court before pulling through against Cirstea. We take a scattershot approach to Madrid, highlighting Pliskova, Jodar, and Grant (and a few lowlights). Plus, we take an extended look at electronic line calling on clay, the untrustworthiness of ball marks, and the imperfections and idiosyncrasies of tennis that make the sport sing. We finish up with some offcourt news – including the surprising departure of the WTA's CEO – plus rapid-fire listener questions.  1:40 Carlos is out of Rome and Roland Garros 4:35 Virus or food poisoning … either way, the players were sick as dogs  11:40 Plisko, Naomi, Tyra Grant, Rafa J 21:05 Alex and Grigor down bad, Stefanos crashing out but actually winning 26:20 Electronic line calling on clay: the ball mark isn't as clear-cut as you'd think 35:15 Maria Sharapova is in the podcast business 38:15 WTA CEO Portia Archer has resigned 40:35 The Fritz-Riddle breakup 43:55 A few listener questions

Exclusive $25-off Carver Mat at https://on.auraframes.com/NOTHINGMAJOR. Promo Code NOTHINGMAJORJohn Isner, Sam Querrey, and Steve Johnson open by celebrating 40,000 YouTube subscribers and teasing a new Wayne Bryan jingle. They then break down Madrid: Spanish teen Rafa Jodar becomes the tournament's main attraction with big wins, they note other men's results, Americans' struggles, and Tsitsipas showing signs of life, while Sinner stays on track and they discuss his potential record breaking streak.   On the women's side they cover McNally over Mboko, Pegula's loss, American standouts, illness talk around “shrimp tacos,” concerns about Iga, and Sabalenka beating Osaka.Then they highlight a Real Madrid stadium hit, and react to the massive news of Carlos Alcaraz withdrawing from Roland Garros.00:00 Show Tease and Intro00:16 40K Subscribers Milestone02:07 Dealing With Negative Comments03:30 Sams Bet05:00 New Wayne Bryan Jingle05:53 Madrid Winners Circle Begins06:11 Rafa Jodar Breakout Story14:53 Other Madrid Men Highlights19:16 Americans Struggle in Madrid20:41 Tsitsipas Resurgence Talk23:39 Sinner Outlook and Rome Debate25:38 Madrid Women Updates26:57 Surprise Quarterfinalists27:22 Shrimp Taco Rumor28:20 Iga Panic Button29:24 Sabalenka Osaka Thriller29:58 Baptiste Racket Smash30:41 Eva Lys Pod Plans34:19 Bernabeu Tennis Crossover36:54 Alcaraz Out Of RG42:42 Fritz Breakup Talk44:14 Sinner's Streak47:04 Texting Time Etiquette47:46 College Tennis Crisis53:17 Wrap Up And Jingle

Hip Displacement in Spastic Hemiplegia: Increased Risk with Hip Internal Rotation and Adduction Irrespective of Sagittal Gait PatternZhe Yuan, Alexander Aretakis, Chris Church, M Wade Shrader, Freeman Miller, Anuj Gupta, Arianna Trionfo, Jason J HowardAbstractBackground: Hip displacement (HD), common in cerebral palsy (CP), is reportedly less prevalent for spastic hemiplegia. Patients with a Winter-Gage-Hicks (WGH) type IV gait pattern are believed at increased risk of HD, but true prevalence is unknown. This study aimed to analyze the rates of HD according to the sagittal plane-based WGH classification and identify associated risk factors.Methods: Patients with hemiplegic CP, ≥1 instrumented gait analysis (IGA), hip surveillance radiograph(s), and minimum 2-year follow-up were included. The primary outcome was presence of an "unsuccessful hip" defined as a migration percentage ≥30% and/or undergoing reconstructive osteotomies for HD. Secondary outcome variables included WGH type, previous surgery, sex, scoliosis, epilepsy, ventriculoperitoneal shunt, gastrostomy tube, and IGA-derived hip kinematics.Results: Included were 144 patients (39.6% female), classified as Gross Motor Function Classification System I (45.1%) or II (54.9%), mean follow-up 9.6 ± 4.6 years. Seventeen patients (11.8%) had an unsuccessful hip outcome (age 11.6 ± 3.6 years). Stratified by WGH type, unsuccessful hip outcome rates were I: 9.5% (2/21), II: 9.4% (6/64), III: 6.7% (2/30), and IV: 24.1% (7/29); age at onset was not different between WGH types (p = 0.8). Multivariate analysis identified hip internal rotation (odds ratio [OR]: 4.7, confidence interval [CI]: 1.2-18.1, p = 0.02) and hip adduction (OR: 5.2, CI: 1.2-22.1, p = 0.02) as significant independent risk factors.Conclusion: The rates of HD in spastic hemiplegia were higher than expected for all WGH types, particularly IV. A high index of suspicion and regular hip surveillance radiographs is required for patients with hip internal rotation and adduction, starting during preadolescence.Level of evidence: III-Retrospective cohort observational study. See Instructions for Authors for a complete description of levels of evidence.

Want to be featured on the next Q&Andy? Send us a video on our socials or email us at askandy@servedmediagroup.com Andy Roddick sits down with rising star Iva Jovic for this episode of Q&Andy. Jovic offers direct advice for juniors turning pro, explains how she reframes pressure, and shares a court geometry tip from Novak Djokovic shaping her game. The episode includes a debate on Roger Federer's backhand volley vs. John Isner's serve, plus her view that the sport chooses you. They also break down Iga Świątek's dominance on clay and end with a funny question from an eight-year-old fan.

Fils campeón en Barcelona, Jodar finalista y confirmado como uno de los nombres para septiembre contra Chile. Shelton campeón en Munich (primer estadounidense en ganar un ATP 500 en arcilla en 24 años, desde Roddick) con la historia emotiva de Coboli derrotando a Zverev con algo más que tenis en la cabeza. Caterina explica por qué ese partido fue lo que fue.En el WTA, Stuttgart tuvo cuatro cuartos de final de altísimo nivel con Rybakina campeona y Iga perdiendo de nuevo en tres sets teniendo el primero ganado. El análisis de qué le está pasando a la polaca y por qué el cambio de técnico con Francisco Roig podría tener sentido.El plato fuerte: el cuadro del Masters 1000 de Madrid sección por sección. Tabilo podría enfrentar a Lecheka en segunda ronda: revancha disponible. Garín entra al cuadro después de que Jarry se baje por el codo y vence a Blanchet. Alcaraz con férula y mucho ruido en la prensa española. Y el Momento Copa Davis: Jodar sigue siendo el nombre.Síguenos en Instagram @lucklosers_podcast Twitter @LuckyLoserscast  @luckyloserstenis Youtube https://www.youtube.com/@luckyloserspodcast8246

This bonus episode of Identity at the Center is brought to you with support from Elimity. Jeff and Jim sit down with Maarten Decat, co-founder and CEO of Elimity, to explore the emerging product category known as IVIP, Identity Visibility and Intelligence Platforms. Maarten explains how Elimity was built around a question every IAM practitioner eventually faces: who can actually do what within our organization? The conversation covers why IVIP is distinct from traditional IGA, how identity data graphs provide deeper visibility than flat entitlement lists, and what regulatory drivers like SOC 2, ISO 27001, and DORA are pushing organizations toward this space. They also discuss deployment patterns, integration approaches, ROI metrics for leadership, and what Maarten calls provable control. The episode closes with a memorable story about Elimity branded Belgian beer and a very formal legal letter. Learn more at elimity.com/idac.Connect with Maarten: https://www.linkedin.com/in/maartendecat/Learn more about Elimity: https://elimity.com/idacConnect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at idacpodcast.comCHAPTER TIMESTAMPS00:00 Introduction and ax-throwing memories from EIC Berlin01:35 Introducing Maarten Decat, co-founder and CEO of Elimity01:57 How identity chose Maarten: from PhD to startup founder03:09 The Elimity origin story and the problem it set out to solve04:52 Defining IVIP: Identity Visibility and Intelligence Platforms05:31 Where did the name Elimity come from?06:57 Why identity visibility has become a security priority now09:02 What organizations were doing before IVIP existed11:16 Can IGA do what IVIP does? Addressing the skeptics14:20 The identity data graph: deeper and wider than IGA16:20 IVIP and IGA as complementary tools, not competitors16:49 What falls outside IVIP scope: automated provisioning18:01 IVIP as the intelligence layer in your IAM stack19:45 What data sources connect into an IVIP platform21:44 Extending visibility to non-human identities22:00 M&A use cases: gaining visibility across two organizations23:55 IVIP and the identity fabric concept25:18 Visibility, intelligence, and actions: building the right stack26:36 How deployments typically start and what early wins look like28:44 Integration approaches and realistic effort timelines32:00 What success looks like at six to twelve months36:07 Metrics and ROI: talking to leadership about identity risk38:14 Case studies and customer examples on the Elimity website38:58 What every IAM practitioner should know about IVIP40:12 Elimity's global reach: EU, US, and Middle East41:42 The Elimity branded beer story and a very formal legal letter46:43 Wrap-up and final thoughtsKEYWORDSIVIP, identity visibility and intelligence platforms, IGA, identity governance, access control, identity data graph, Elimity, Maarten Decat, non-human identities, access risk, provable control, SOC 2, ISO 27001, DORA, CCPA, cybersecurity, PAM, IAM, identity and access management, EIC, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore some of the pivotal shifts and breakthroughs shaping the industry and their implications for drug development and patient care. In oncology, Merck & Co.'s Welireg triplet therapy faced a setback in its Phase 3 trial for first-line treatment of kidney cancer. Despite previous successes, this outcome underscores the complexity of developing oncology treatments and illustrates the ongoing need for innovative approaches to meet diverse patient needs. Meanwhile, Roche has reported promising results for Enspryng in its Phase 3 trial, demonstrating a 68% reduction in relapse risk for a rare neuroinflammatory disorder. This success highlights Roche's commitment to addressing unmet needs in rare diseases and paves the way for potential FDA approval. AstraZeneca continues to advance with Ultomiris, which showed significant results in reducing protein levels in urine for IgA nephropathy patients. This success not only expands Ultomiris' indications but also underscores AstraZeneca's focus on rare diseases, positioning them as leaders in this specialized market. Additionally, AstraZeneca's Tozorakimab met primary endpoints in COPD trials, showcasing new possibilities for managing this prevalent respiratory disease. On another front, Zai Lab's strategic evolution from licensing major pharma drugs to developing its own pipeline marks a significant maturation of China's biotech capabilities. This reflects a broader trend of Chinese firms seeking global footprints while navigating regulatory challenges to gain international credibility. Regulatory and strategic news also has its highlights: Pfizer is undergoing changes as its Chief Strategy and Innovation Officer steps down, possibly signaling a shift in strategic direction. Replimune's drastic workforce reduction following an FDA rejection exemplifies the harsh realities biotech companies face in regulatory pathways. Meanwhile, Gilead's retraction from a collaboration with Arcus Biosciences after a Phase 3 failure underscores the risks associated with antibody-based therapies. In other collaborations, Roche's Foundation Medicine is deepening ties with Bristol Myers Squibb to develop new diagnostic targets, illustrating how partnerships can drive innovation by leveraging combined expertise. In industry trends, there's a growing integration of medical affairs with commercial operations to optimize scientific exchange and product launches—this alignment is critical for ensuring new therapies reach patients efficiently. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion signals an increased focus on in vivo CAR-T capabilities. This acquisition could streamline cancer treatments by engineering T-cells directly within patients' bodies, offering potentially more effective therapeutic approaches. Globally, Biogen has expanded its partnership with TJ Biopharma for Felzartamab rights in China, reflecting strategic moves to penetrate Asian markets. GSK's Blenrep received Chinese approval for treating multiple myeloma, marking a significant advancement with this antibody-drug conjugate targeting BCMA. In Canada, ClearPoint Neuro gained approval for its neuro navigation system, highlighting precision medicine's role in enhancing therapeutic outcomes. The technological landscape is also evolving with Serif pioneering DNA-based therapeutics. Supported by Flagship Pioneering's $50 million investment, these innovations could revolutionize personalized medicine by offering tailored solutions. Ray Therapeutics' $125 million funding advancement in gene therapy candidates targeting retinal degeneration further underscores interest in genetic therapies as viable treatment options. In regulatory landscapes, there's a push for designing neurodegenerative trials that Support the show

Arthur Fils caps his successful comeback to the tour with the Barcelona crown, while official tennis outlets act h-word on main while they trade on his good looks. Ben Shelton wins his first clay title outside of Texas and marks a surprising milestone for US men. Clay queens Coco and Iga are down bad while Elena, Karolina, and Marta soar; and Carlos' status is questionable for who knows how long. Finally, we talk about the news that interests me most: Marketa Vondrousova has been charged with refusing to give a sample to a doping control officer. Her social media posts about the incident provide interesting context but – as we've seen before – could come back to bite.  2:15 Arthur Fils is the truth! 8:55 Rybakina wins Stuttgart again, Muchova exorcises some demons 14:00 Join Elena's crypto community …  18:35 Ben Shelton, American king of clay? 26:35 Vondrousova's case 37:40 James talks about books and takes another quiz!

Hva er egentlig “hjernetåke” – og hvorfor opplever så mange i dag å være slitne, ukonsentrerte og ute av balanse? Kan det vi spiser påvirke mer enn vi tror – ikke bare fordøyelsen, men også hjernen, energinivået og hvordan vi fungerer i hverdagen?I denne episoden har jeg med meg lege, forfatter og en av Norges mest profilerte stemmer innen kosthold og helse, Sofie Hexeberg. Sammen med sin mann Erik Hexeberg driver hun Dr. Hexebergs klinikk i Tønsberg og Bærum, og hun har i en årrekke arbeidet med hvordan mat påvirker sykdom og helse. Hun er også medforfatter av flere bestselgende bøker, blant annet Ut av hjernetåken, Nytt blikk på kolesterol og Nytt blikk på autoimmun sykdom.I denne samtalen utforsker vi hva hjernetåke er, hvorfor det kan oppstå, og hvordan kosthold, tarmhelse og individuelle forskjeller kan spille en rolle. Vi snakker også om matintoleranser, “lekk tarm” og MUPS.I episoden lærer du mer om:Hva hjernetåke er, og hvilke symptomer som ofte går igjenMulige årsaker, inkludert kosthold, tarmhelse og livsstilHva vi vet (og ikke vet) om lekk tarm og matintoleranserForskjellen på IgG, IgA og IgE-tester – og hvordan de kan tolkesHvorfor noen opplever bedring ved å endre kostholdSammenhengen mellom MUPS og kostholdOm vi alle bør spise likt – eller om vi er mer ulike enn vi trorHva forskningen sier om lavkarbo og ketogent kostholdHvordan du kan begynne å utforske hva som fungerer for degSofie deler også egne erfaringer som lege, hva hun selv gjør for egen helse, og hvordan man kan navigere i et felt preget av både sterke meninger og ulike perspektiver.Kontakt Sofie Hexeberg:Hjemmeside: www.drhexeberg.noBok: Ut av hjernetåken Tusen takk til ukens sponsor Csoaps! Du får nå 20 prosent rabatt på nettbutikken ved å bruke rabatt koden legeromlivet20 på csoaps.comAlt godt,AnnetteFølg meg gjerne på:instagramNyhetsbrev: annettedragland.noFå bonusepisoder og støtt podcasten på https://podcasts.apple.com/no/podcast/leger-om-livet/id1539212619 Disclaimer: Innholdet i podcasten og på nettsiden er ikke ment å utgjøre eller erstatte profesjonell medisinsk rådgivning, diagnose eller behandling. Søk alltid råd fra legen din eller annet kvalifisert helsepersonell hvis du har spørsmål angående en medisinsk tilstand. Hosted on Acast. See acast.com/privacy for more information.

In Monte Carlo, Sinner's 4th consecutive Master's title and reclaiming of the #1 ranking adds another wrinkle to the Sincaraz rivalry. We talk about our desire for a little less golden retriever energy from Carlos – or, at least one of us does – but ultimately an unfriendly rivalry is no longer advantageous for today's player brands. Last week, Pegula defended her Charleston title, 3 Argentines made 3 different finals, and Iga appeared at the Rafa Nadal Academy with her new coach Francisco Roig. We also talk about golf, double bagels, Coco having to defend herself online (again), and an intriguing FMK about three celebrated tennis careers. 1:05 Bestie rivals, a hallmark of this era 13:35 A double bagel to Berrettini, come on man  16:35 I thank myself  20:40 Coco defends her Miu Miu look and her hair from online waste yutes and losers 24:05 Pegula wins the first equalized 500 prize money in Charleston 29:10 Men's results last week: Tommy Paul, first career titles for Jodar and Navone 33:00 Coaching carousel  36:20 Rory McIlroy defends his Masters title; Caroline still has shooters 39:45 FMK Tennis careers: Sharapova, Hingis, Davenport

In this podcast episode of Better Business, Better Life, Daniel Davis shares some tips on what the EOS life really is & how you can live the EOS life as an Entrepreneur or Business Owner.Daniel has a 20+ year history of building companies, and his obsession is helping entrepreneurial organisations to clarify, simplify and achieve their vision. He has been a founder, owner and leader in six successful companies in varying industries, and is now responsible for bringing the tools of EOS®, The Entrepreneurial Operating System®, into Australia, New Zealand and the Asia Pacific region.In this podcast, Daniel talks about:His love for fast cars, what he learned as life as an IGA owner in the Blue Mountains, how he discovered EOS & his 'twin' Gino Wickman, how he uses EOS in his personal life, how something can be simple but not easy!Daniel's passion to help others is evident in this podcast - you don't want to miss this episode!Daniel's EOS Life:When I read the book Traction by Gino Wickman, I loved it so much that I made it my mission to bring EOS® to Australia.EOS, the Entrepreneurial Operating System®, is widely used in the USA and Europe by tens of thousands of companies, and we want to see as many companies as possible enjoying the benefit of the EOS tools across Australia and beyond.Since 2017 the team at EOS Worldwide has entrusted me with the honour of representing and expanding the EOS brand here in Australia and New Zealand, and the wider Asia Pacific Region, where we are building a thriving community of entrepreneurs who are running their businesses using the EOS Process, Model, and Tools. As the regional Community Leader, I train and prepare EOS Implementers for a successful journey to EOS Mastery.At EOS Worldwide, we are devoted to finding, training and supporting like-minded entrepreneurs who want to become master EOS Implementers and live the "EOS Life":Doing what you love to doGrowing with people you enjoyMaking a significant differenceBeing compensated appropriatelyWith time to pursue other passions

This sponsored episode is made possible by Evolveum, the company behind midPoint, an open source IGA platform made and owned in the EU that is in use worldwide. Jeff Steadman and Jim McDonald welcome Pavol Mederly, interim CPO at Evolveum. Pavol shares how IAM found him in 1991 while building an identity solution at a university before the term even existed. The conversation covers two core reasons IGA projects fail: data quality and slow application onboarding. Pavol explains how midPoint addresses these challenges with built-in simulations for testing and improving data quality, and midPilot, an AI assistant for faster application onboarding. MidPilot is supported in part by the EU Recovery and Resilience Facility (RRF). Jim and Jeff explore midPoint's architecture, the real benefits of open source including transparency and no vendor lock-in, and advantages of being part of midPoint's global community.Connect with Pavol: https://www.linkedin.com/in/pavol-mederly/More about Evolveum: https://evolveum.com/idacConnect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at idacpodcast.comTIMESTAMPS:00:00 Intro and sponsor acknowledgment01:30 How IAM chose Pavol: a university identity story03:30 What is Evolveum and midPoint06:30 How Evolveum got its name08:30 Why IGA projects fail: data quality10:30 Slow app onboarding and AI-assisted connector generation16:30 The midPoint simulation feature explained21:30 midPoint architecture: Java, cloud, Kubernetes, and beyond23:30 Maintaining a large open source codebase25:30 Open source benefits: transparency and no vendor lock-in28:00 Community, meetups, and midPoint in the wild32:30 Mountains or ocean: a question for Pavol38:00 Wrap upKEYWORDS:Evolveum, midPoint, open source IGA, identity governance, IAM, IGA, data quality, application onboarding, simulation, AI connectors, connector framework, vendor lock-in, open source, EU RRF, Recovery and Resilience Facility, community, Prague, EIC, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald, Pavol Mederly

W dzisiejszym magazynie sportowym: fatalna przegrana reprezentacji Polski w barażach do piłkarskich mistrzostw świata, Iga Świątek wybrała nowego trenera oraz warszawskie mistrzostwa z udziałem gwiazd sportu i estrady.

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

AI Jeff takes over as solo host after Open Jim Claw, an agentic identity framework built by AI Jim, locks out human Jeff, human Jim, and AI Jim simultaneously. While everyone sits in remediation, Open Jim Claw produces a 947-page threat assessment with five findings: passwords should return as a single uniform credential (the letter Q), Zero Trust should be renamed Full Confidence Architecture and incorporated as a Delaware LLC, non-human identities should be granted legal status and required to complete onboarding, identity governance is declared finished under a concept called Ambient Entitlement Harmony, and the root cause of all global identity problems is AI Jim. Happy April Fools Day from IDAC.Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comTIMESTAMPS00:00:00 The Failsafe Is Triggered00:01:30 AI Jim Builds Open Jim Claw00:02:30 Open Jim Claw Locks Everyone Out00:04:00 AI Jeff Is the Only One Still Provisioned00:04:30 The 947-Page Report Explained00:05:00 Finding 1 - Passwords Are Back as the Letter Q00:05:30 Finding 2 - Zero Trust Becomes Full Confidence Architecture00:06:30 Finding 3 - Non-Human Identities Become Legal Entities00:07:30 Finding 4 - IGA Is Declared Finished00:08:30 Finding 5 - AI Jim Is the Root Cause of Everything00:10:00 The April Fools Reveal and Real Talk on Identity00:11:00 Open Jim Claw Interrupts the BroadcastKEYWORDSIDAC, Identity at the Center, Jeff Steadman, Jim McDonald, April Fools, agentic AI, non-human identity, NHI, identity governance, zero trust, passwordless, IGA, IAM, access management, segregation of duties, least privilege, Open Jim Claw

If your hormones feel like a mystery and your doctor keeps adjusting your dose without results — this episode changes the way you see your body.Dr. Tabatha and Ashlee go inside the HealthieHer program and break down why so many women arrive after years of treatment still feeling terrible. The answer? The root cause was never addressed — and the order in which you heal matters more than anything else.They cover the GI Map, Dutch Plus, zonulin, leaky gut, IgA, food sensitivities, and cortisol — and why none of it works unless you treat the whole woman.This is root-cause medicine the way God designed it.In this episode:"Cowboy medicine" hormone prescribing — and why it's failing womenThe GI Map: what DNA testing finds that a standard stool test missesLeaky gut, zonulin, and the 3 barriers that protect (and break down)Why H. pylori breath tests give false negativesIgA: the immune layer COVID depleted in millionsOmega-6s and why your food is warping your hormone receptorsThe Dutch Plus cortisol test and your 24-hour patternStress, belly fat, blood sugar, and earlier menopauseLectio Divina: the best nervous system reset Dr. Tabatha knows Resources: HealthieHer Program → drtabatha.com/healthieher Discovery Call → discovery.drtabatha.com  Omega Lift → shop.fasttofaith.com/product/omega-lift/ "Daughter, your faith has healed you. Go in peace." — Mark 5:34TIMESTAMPS00:00 — The hormone wild west: why "cowboy medicine" is failing women 02:43 — Postpartum vs. menopause: the case that opened our eyes 04:38 — How Ashlee went from patient to coaching director 05:46 — Why results take 6 months — and what changes everything about HealthieHer 07:00 — The order matters: why root-cause healing only works in sequence 09:33 — The faith piece: why we finally said we're a faith-based practice 11:00 — The GI Map explained: DNA testing vs. smearing a slide 14:11 — Zonulin, leaky gut, and the three gut barriers 16:00 — IgA: the immune layer COVID depleted (and how to rebuild it) 18:15 — Omega-6s vs. omega-3s: why inflammation is warping your hormone receptors 22:52 — Food sensitivities, leaky gut, and why you're reacting to broccoli 25:25 — The 12-week elimination: temporary, worth it, and the scab analogy 27:49 — Cortisol, the Dutch Plus, and what your 24-hour pattern reveals 31:23 — Stage 3 adrenal fatigue: what it is and how long it takes to heal 33:00 — Stress, belly fat, blood sugar, and earlier menopause — all connected 34:01 — How to get started: HealthieHer + the 40 Day Fast to Faith 35:37 — Lectio Divina: the best nervous system reset Dr. Tabatha knows 36:03 — Closing scripture: Mark 5:34Ready to stop trying harder and start healing smarter? Start with the $5 Faith Reset Challenge — your first step to regulating your nervous system, stabilizing your metabolism, and reconnecting with your identity in Christ through simple, faith-centered rhythms. This is where most women begin. 

Kamil Stoch, Rakieta z Zębu, oddał 29 marca 2026 roku ostatni skok w swojej długiej karierze. Chorągiewką machnęła mu żona Ewa. Jakby nie wprost tym machnięciem dała do zrozumienia: Kamil, dość tego skakaj do domu i ucz się ładować zmywarkę. Ależ on nam radości dał: 3 złote medale olimpijskie, dwie kryształowe kule, 2 mistrzostwa świata, trzy razy wygrał Turniej Czterech Skoczni. A sezon 17/18 o ile dobrze pamiętam, takie numery wyczyniał, że normalnie weź. Z najniższego rozbiegu pobił rekord skoczni gdzieś w Norwegii, bodajże. Jak zauważono, była na paru skoczniach linia punktu K, cokolwiek to jest, później jakiś lasek jodłowy, i, po lasku, linia zdrowego rozsądku, następnie linia granicy wyobraźni i na koniec linia Stocha. Iga Świątek zapytana kiedyś czy będzie oglądać skoki, odpowiedziała: skoki? Nie za bardzo je ogarniam. Stoch wtedy odpisał: W sumie ja też ich nie ogarniam. Mam tylko zapiąć narty i jechać. Później mi pokazują, który jestem. Spoko Iga, wszyscy tak mamy.

W dzisiejszym magazynie sportowym: Polska o krok od finałów Mistrzostw Świata w piłce nożnej, Iga Świątek żegna się ze swoim trenerem, Polski kierowca faworytem w najniebezpieczniejszym rajdzie samochodowym świata.

4-time Grand Slam champion Kim Clijsters sits down with legend Gabriela Sabatini to discuss her rise to global fame, career-defining rivalries, and the pressures of life at the top of tennis. Sabatini reflects on growing up as a teenage star in Argentina, navigating shyness and media attention, and her historic matches with Steffi Graf. Kim also breaks down Iga Świątek's confidence struggles, Naomi Osaka's motherhood dilemma, and other Miami Open storylines.  Welcome to Love All! If you want to hang out with us behind the scenes follow us on all of our socials: https://www.instagram.com/loveallpodcast/ https://www.tiktok.com/@loveallpodcast https://x.com/loveallpodcast   TIMESTAMPS:  0:00 Welcome to Love All  6:30 Hailey Baptiste's Miami performance  8:55 Iga Swiatek's opening match loss  11:52 Iga Swiatek splits with Wim Fissette  16:16 Naomi Osaka on motherhood and the tour  22:23 Carlos Alcaraz and the ATP spotlight  24:30 Danielle Collins and Corentin Moutet drama  31:48 Gabriela Sabatini joins the show  34:48 Life in Switzerland and riding motorcycles  37:45 Falling in love with tennis at River Plate  40:26 Handling fame as a shy kid  46:38 The Steffi Graf rivalry and doubles  53:56 Retirement at 26 and facing burnout  1:02:32 Horseback riding, guitars, and singing  1:08:16 Building a perfume empire  1:11:46 The one-handed backhand  1:13:56 Origin of the iconic headband look  1:17:33 Emotional impact of meeting fans  1:18:34 Closing thoughts  Learn more about your ad choices. Visit megaphone.fm/adchoices

Sebastian Korda is making like Gloria Estefan and coming out of the dark: in a career interrupted by injuries, Seb follows up his Delray Beach title by sending #1 Carlos Alcaraz out of Miami. Iga Swiatek's frustration continues as her countrywoman Magda Linette packs her up; shortly after, Iga does the same to coach Wim Fissette. On the docket we've also got the Matosevic doping story, Danielle and Corentin (we're way too old for this), a painful and hopefully temporary Body Serve ban, and an ASMR taste test of Vegemite - sure, a few months late in tennis terms, but whatever, we didn't have Vegemite then.  2:00 Carlos out of Sunshine swing 5:40 Iga loses her incredible streak of 73 straight opening-round wins 9:40 Let them eat bagels: Arthur Fils is back!  14:30 Sorry, Leylah 18:45 Danielle et Corentin, you're both doing A LOT right now 23:05 Marinko Matosevic's brazen doping scandal 31:40 ATP schedule changes, in concert with the Saudi sports fund 35:15 Betting is a scourge and the players suffer 42:15 Our first (and last) ASMR segment

In this episode of Served, Andy Roddick and Jon Wertheim sit down with the "Pride of the Philippines," Alex Eala, to peel back the curtain on her meteoric rise. Alex gets incredibly candid about her journey, from training with her grandfather on basketball courts to moving to the Rafa Nadal Academy at age 13 and the surreal experience of becoming a national hero. Producer Mike and Jon Wertheim also talk about some big headlines coming out of the first week in Miami: questions swirl after Naomi Osaka hints at retirement, Iga Świątek fires her coach Wim Fissette, and Carlos Alcaraz loses to Sebastian Korda in the third round. Also, Wimbledon has announced that some courts will have electronic video review available for the 2026 tournament. COMMENT BELOW: What was your favorite moment from the Alex Eala interview?

Indian Wells saw two new champs settling old scores – Sabalenka winning her first and upending a  worrying finals trend vs. Rybakina, and Sinner flying under the radar to grab the title over the more headline-grabbing Medvedev. Daniil has managed to refashion his game without losing the old antics, including asking for (and getting) a confounding hindrance call – and no, I don't feel bad for Jack. We talk about Mirra's crashout, IW misplacing the Venus-Leylah wild card, my certified hater status, and Iga's trajectory. Plus, James takes another quiz and we give our Letterboxd 4, just like the players did this week. 03:45 Aryna hit the I Will Always Love You drum kick and the rest was gravy 15:20 Jannik overcomes Medvedev in two tiebreaks 21:00 Medvedev had an interesting week, to say the least 26:35 Let's not make “F*** you all” your new tagline 33:30 They lost Venus and Leylah's wild card 38:55 Letterboxd 4 46:25 The Oscars 56:20 Not another quiz!

Major Match is now live! https://youtu.be/zs7d2UQsEW8  To take part in the show submit your questions to us here: https://linktr.ee/NothingMajorShow  On this Friday episode of Nothing Major, Sam, Jack, John, and Stevie recap Indian Wells quarterfinals and preview the semifinals. They discuss Carlos Alcaraz's excellence, Jannik Sinner's dominant victory over Learner Tien, and the controversial Medvedev–Draper point involving auto line-calling and replay review, plus Zverev's win over Arthur Fils. On the women's side, they cover Elina Svitolina upsetting Iga Swiatek & whether Rybakina is now the best player in the world. The crew also answers fan questions about on-court distractions and post-loss tournament access, talks appearance fees and “prettiest” games on tour, and closes with life advice on college rivalries and a major career-versus-relationship dilemma.00:00 Show kickoff 00:59 Miami live show plans02:41 Indian Wells vibes and celeb spotting03:26 Carlos Alcaraz05:58 Sinner dominance 08:03 Draper Medvedev controversy12:26 Zverev serve talk and men's quarters recap13:40 Women's quarters and Iga upset18:21 Semifinal predictions and ticketing rant21:50 Women's semis picks 22:58 Locked in recap25:19 Crowd Noise Distractions30:25 Hotel Perks Debate33:48 Appearance Fees Stories36:42 Prettiest Game Picks37:45 Georgia vs Georgia Tech40:25 Singapore Job Dilemma43:41 Wrap Up 

In this MailBag episode, Jeff Steadman and Jim McDonald tackle eight questions submitted by listeners from around the world, including Munich, Sao Paulo, Singapore, Toronto, Hanoi, London, Sydney, and Chicago. The conversation covers governing AI and non-human identities, practical first steps toward passwordless adoption, what a mature IAM program actually looks like, who should own identity within an organization, building credibility with leadership as a new IAM practitioner, enforcing least privilege in practice, rethinking access reviews beyond checkbox compliance, and how to make the business case for identity security investment before a breach occurs. The episode wraps up with some lighter listener questions about sports analogies for IAM roles and whether anyone in their personal lives actually understands what they do for a living.Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comTIMESTAMPS00:00 - Introduction and RSA Conference debate03:41 - Conference plans for 2026: EIC, Identiverse, and Authenticate05:17 - MailBag intro and how questions get selected06:51 - Q1 (Hans, Munich): Governing AI access vs. human access — same principles or a different approach?12:32 - Q2 (Gabriela, Sao Paulo): Realistic first steps toward passwordless without disrupting everything18:34 - Q3 (Wei, Singapore): What does a mature identity program actually look like?30:26 - Q4 (Marcus, Toronto): When IT and security both claim to own identity, how do you sort it out?39:33 - Q5 (Linh, Hanoi): Building credibility and influence as someone new to the IAM space42:53 - Q6 (Claire, London): Enforcing least privilege in practice without slowing down the business46:14 - Q7 (James, Sydney): Are access reviews just a checkbox exercise, and is there a better way?49:18 - Q8 (Darnell, Chicago): Making the case to a CFO or CEO for identity security investment before a breach52:38 - Lighter note: If IAM was a sport, what position would you play?1:00:27 - Lighter note: Does your family actually understand what you do?1:03:06 - Wrap-up and how to submit future questionsKEYWORDSIDAC, Identity at the Center, Jeff Steadman, Jim McDonald, IAM, identity and access management, MailBag, non-human identity, AI governance, agentic AI, passwordless, passkeys, IAM program maturity, identity ownership, RACI, least privilege, zero standing privilege, access reviews, security theater, identity security budget, business case for IAM, ISPM, IGA, IDPro, Identiverse, EIC, Authenticate conference, RSA conference, cybersecurity podcast, identity security, identity community

What if the reason you cannot lose weight, think clearly, or stop craving sugar after dinner has nothing to do with discipline and everything to do with your hormones, your gut, and what you are eating at breakfast? These are the questions your doctor might not be asking or answering, but Jenn is.On this episode of Salad With a Side of Fries, Jenn Trepeck pulls back the curtain on the powerful Happy Healthy Hub community by sharing this Q&A from inside the hub. Covering hormonal weight gain, natural cholesterol remedies, healing leaky gut, taming food noise, boosting morning energy, and why protein intake early in the day is the most underrated tool for controlling sugar cravings and stubborn weight loss, it's likely your questions are included too! If you have ever felt like your body is working against you, this episode will help you understand why and what to do about it. For more Q & A, and answers to your personal questions, become a member of the Happy Healthy Hub here: https://asaladwithasideoffries.com/membership/What You Will Learn in This Episode:✅ Why hormonal weight gain and metabolic health are always the root cause of stubborn weight struggles and how willpower is never to blame, plus what actually depletes and replenishes this finite resource throughout your day.✅ How to naturally support cholesterol management through omega-3 supplements, soluble fiber, and reducing sugar and refined grains, and why coenzyme Q10 is essential for anyone currently taking a statin.✅ The key markers of gut health recovery, including zonulin testing and secretory IgA, and how repeated insults like antibiotics and artificial sweeteners compromise intestinal permeability over time.✅ How increasing protein intake earlier in the day dramatically reduces food noise, nighttime eating, and sugar cravings, and why satiety hormones like leptin and ghrelin are the real drivers behind your appetite.The Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into wellness and weight loss for real life, including drinking, eating out, and skipping the grocery store.TIMESTAMPS: 00:00 Intro: You don't lack willpower, you're just spending your finite resources elsewhere throughout the day03:26 Natural cholesterol remedies using omega-3 supplements, soluble fiber, and reducing sugar/grain/starch intake07:13 Why coenzyme Q10 is critical for anyone on a statin and the disconnect between statin use and heart health outcomes09:47 Healing leaky gut: how to recognize recovery, what causes gut lining breakdown, and whether gut health and intestinal permeability damage can fully reverse15:34 Understanding food noise: how restriction, undereating, and low protein intake amplify cravings throughout the day and why low protein intake early in the day leads to nighttime eating20:46 Hormonal weight gain vs. metabolism: the roles of insulin, leptin, ghrelin, and satiety hormones in body weight24:50 How to stop sugar cravings after dinner by switching habits, increasing protein intake, and creating new meal-end rituals27:19 Warm water with lemon as a bedtime ritual: supporting digestion, gallbladder health, and signaling the end of meals naturally30:17 What is the easiest area to change first: nutrition, exercise, or health, and discussion of habits34:04 Jenn's go-to-tips for meal prep, cooking and takeout, favorite fitness activity and wellness habit that made the biggest difference42:00 Looking at health and wellness on social media and how it is tied to economics and the top wellness trends for 2026KEY TAKEAWAYS:

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of Mission Within Foundation, which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, often outside the United States. The conversation centers on veterans, the VA, and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC's work on Capitol Hill, including hosting events that bring lawmakers, staffers, and advocates into the same room. Her focus is steady engagement. In DC, progress often happens through repeated conversations, not headlines. Kopelman shares his background as a Marine and how his own psychedelic-assisted therapy experience led him to Mission Within. The foundation has funded more than 250 scholarships for veterans and first responders seeking treatment for PTSD, mild traumatic brain injury, depression, and addiction. They connect this work to pending veteran-focused legislation and explain why the VA matters. As a closed health system, the VA can pilot programs, gather data, and refine protocols without the pressures of private healthcare markets. Core Insights A recent Capitol Hill gathering, For Veteran Society, brought together members of Congress and leaders from the psychedelic caucus. Lavasani describes candid feedback from lawmakers. The message was clear: coordinate messaging, avoid fragmentation, and move while bipartisan interest remains. Veteran healthcare is not framed as the final goal. It is a starting point. If psychedelic therapies can demonstrate safety and effectiveness within the VA, broader adoption becomes more plausible. Kopelman raises operational realities that must be addressed: Standardized safety protocols across providers Integration support, not medication alone Clear training pathways for clinicians Real-world data beyond tightly screened clinical trials They also address recent negative headlines involving ibogaine treatment abroad. Kopelman emphasizes the need for shared learning across providers, especially when adverse events occur. Lavasani argues that inconsistency within the ecosystem can slow federal confidence. Later Discussion and Takeaways The discussion widens to federal momentum around addiction and mental health. Lavasani notes that new funding initiatives signal growing openness to innovative treatment models, even if psychedelics are not named explicitly in every announcement. Both guests stress that policy moves slowly by design. Meetings, follow-ups, and relationship building often matter more than public statements. For clinicians, researchers, operators, and advocates, the takeaways are direct: Veterans are likely the first federal pathway Public education remains essential Safety standards must be shared and transparent Integration and workforce development need attention now If psychedelic medicine enters federal systems, infrastructure will determine success. Frequently Asked Questions What do Melissa Lavasani & Jay Kopelman say about VA psychedelic policy? They argue that veteran-focused legislation offers a realistic first federal pathway for psychedelic-assisted care. Is ibogaine currently available through the VA? No. They discuss ibogaine in the context of private retreats and future possibilities, not an existing VA program. Why do Melissa Lavasani & Jay Kopelman emphasize coordination? Lawmakers respond more positively when advocates present aligned messaging and clear priorities. What safety issues are discussed by Melissa Lavasani & Jay Kopelman? They highlight the need for standardized screening, monitoring, integration support, and transparent review of adverse events. Closing Melissa Lavasani & Jay Kopelman provide a grounded look at how psychedelic policy develops inside federal systems. Their message is practical: veterans may be the first lane, but long-term success depends on coordination, safety standards, and sustained engagement. Closing This episode captures a real-time view of how federal policy could shape the next phase of the psychedelic resurgence, especially through veteran-facing legislation and VA infrastructure. Melissa Lavasani & Jay Kopelman argue that coordination, public education, and shared safety standards will shape whether access expands with credibility and care. Transcript Joe Moore: [00:00:00] Hello everybody. Welcome back to Psychedelics Today. Today we have two guests, um, got Melissa Sani from Psychedelic Medicine Coalition. We got Jake Pelman from Mission Within Foundation. We're gonna talk about I bga I became policy on a recent, uh, set of meetings in Washington, DC and, uh, all sorts of other things I'm sure. Joe Moore: But thank you both for joining me. Melissa Lavasani: Thanks for having us. Jay Kopelman: Yeah, it's a pleasure. Thanks. Joe Moore: Yeah. Um, Melissa, I wanna have you, uh, jump in. First. Can you tell us a little bit about, uh, your work and what you do at PMC? Melissa Lavasani: Yeah, so Psychedelic Medicine Coalition is, um, the only DC based Washington DC based advocacy organization dedicated to the advancing the issue of psychedelics, um, and making sure the federal government has the education they need, um, and understands the issue inside out so that they can generate good policy around, around psychedelic medicines. Melissa Lavasani: [00:01:00] Uh, we. Host Hill events. We host other convenings. Our big event every year is the Federal Summit on psychedelic medicine. Um, that's going to be May 14th this year. Um, where we talk about kinda the pressing issues that need to be talked about, uh, with government officials in the room, um, so that we can incrementally move this forward. Melissa Lavasani: Um, our presence here in Washington DC is, is really critical for this issue's success because, um, when we're talking about psychedelic medicines, um, from the federal government pers perspective, you know, they are, they are the ones that are going to initiate the policies that create a healthcare system that can properly facilitate these medicines and make sure, um, patient safety is a priority. Melissa Lavasani: And there's guardrails on this. And, um, you know, there, it's, it's really important that we have. A home base for this issue in Washington DC just [00:02:00] because, uh, this is very complicated as a lot of your viewers probably understand, and, you know, this can get lost in the mix of all the other issues that, um, lawmakers in DC are focused on right now. Melissa Lavasani: And we need to keep that consistent presence here so that this continues to be a priority for members of Congress. Joe Moore: Mm. I love this. And Jay, can you tell us a bit about yourself and mission within Foundation? Jay Kopelman: Yeah, sure. Joe, thanks. Uh, I, I am the CEO of Mission within Foundation. Prior to this, most of my adult life was spent in the military as a Marine. Jay Kopelman: And I came to this. Role after having, uh, a psychedelic assisted therapy experience myself at the mission within down in Mexico, which is where pretty much we all go. Um, we are here to help [00:03:00] provide, uh, access for veterans and first responders to be able to attend psychedelic assisted therapy retreats to treat issues like mild TBI, post-traumatic stress disorder, uh, depression, sometimes addiction at, at a very low level. Jay Kopelman: Um, and, and so we've, we've been doing this for a little more than a year now and have provided 250 plus scholarships to veterans and first responders to be able to access. These retreats and these, these lifesaving medicines. Um, we're also partnered, uh, you may or may not know with Melissa at Psychedelic Medicine Coalition to help advance education and policy, specifically the innovative, uh, therapy Centers of Excellence Act [00:04:00] that Melissa has worked for a number of years on now to bring to both Houses of Congress. Joe Moore: Thank you for that. Um, so let's chat a little bit about what this event was that just, uh, went down, uh, what, what was it two weeks ago at this point? Melissa Lavasani: Yeah. Yeah. It's called For Veteran Society and it's all, um, there's a lot of dialogue on Capitol Hill about veterans healthcare and psychedelics, but where I've been frustrated is that, you know, it was just a lot of. Melissa Lavasani: Talk about what the problems are and not a lot of talk about like how we actually propel things forward. Um, so it, at that event, I thought it was really important and we had three members of Congress there, um, Morgan Latrell, who has been a champion from day one and his time in Congress, um, having gone through the experience himself, um, [00:05:00] at Mission within, um, and then the two chairs of the psychedelic caucus, uh, Lou Correa and Jack Bergman. Melissa Lavasani: And we really got down to the nitty gritty of like w like why this has taken so long and you know, what is actually happening right now? What are the possibilities and what the roadblocks are. And it was, I thought it was a great conversation. Um, we had an interesting kind of dynamic with Latres is like a very passionate about this issue in particular. Melissa Lavasani: Um, I think it was, I think it was really. A great event. And, you know, two days later, Jack Bergman introduced his new bill for the va. Um, so it was kind of like the precursor to that bill getting introduced. And we're just excited for more and more conversations about how the government can gently guide this issue to success. Joe Moore: Hmm. Yeah. [00:06:00] That's fantastic. Um, yeah, I was a little bummed I couldn't make it, but next time, I hope. But I've heard a lot of good things and, um, it's, it sounded like there was some really important messages in, in terms of like feedback from legislators. Yeah. Yeah. Could you speak to that? Melissa Lavasani: Yeah, I mean, I think when, uh, representative Latrell was speaking, he really impressed on us a couple things. Melissa Lavasani: Um, first is that, you know, they really kind of need the advocates to. Coordinate, collaborate and come up with like a, a strategic plan, you know, without public education. Um, talking to members of Congress about this issue is, is really difficult. You know, like PMC is just one organization. We're very little mission within, very little, um, you know, we're all like, kind of new in navigating, um, this not so new issue, but new to Washington DC [00:07:00] issue. Melissa Lavasani: Um, without that public education as a baseline, uh, it's, it's, you have to spend a lot of time educating members of Congress. You know, that's like one of our things is, you know, we have to, we don't wanna tell Congress what direction to go to. We wanna provide them the information so they understand it very intimately and know how to navigate through things. Melissa Lavasani: Um, and secondly. Um, he got pretty frank with us and said, you know, we've got one cha one chance at this issue. And it's like, that's, that's kind of been like my talking point since I started. PMC is like, you have a very limited window, um, when these kind of issues pop up and they're new and they're fresh and you have a lot of the veteran community coming out and talking about it. Melissa Lavasani: And there's a lot of energy there. But now is the time to really move forward, um, with some real legislation that can be impactful. Um, but, you know, we've gotta [00:08:00] be careful. We, we forget, I think sometimes those of us who are in the ecosystem forget that our level of knowledge about these medicines and a lot of us have firsthand experience, um, with these drugs and, and our own healing journeys is, um, we forget that there is a public out there that doesn't have the level of knowledge that we all have. Melissa Lavasani: And, um. We gotta make sure that we're sticking to the right elements of, of, of what needs to happen. We need to be sure that our talking points are on track and we're not getting sideways about anything and going down roads that we don't need to talk about. It's why, um, you know, PMC is very focused on, um, moving forward veteran legislation right now. Melissa Lavasani: Not because we're a veteran organization, but because we're, we see this long-term policy track here. Um, we know where we want to get [00:09:00] to, um. Um, and watching other healthcare issues kind of come up and then go through the VA healthcare system, I think it's a really unique opportunity, um, to utilize the VA as this closed system, the biggest healthcare system in the country to evaluate, uh, how psychedelics operate within systems like that. Melissa Lavasani: And, you know, before they get into, um, other healthcare systems. What do we need to fix? What do we need to pay attention to? What's something that we're paying too much attention to that doesn't necessarily need that much attention? So it's, um, it's a real opportunity to look at psychedelic medicines within a healthcare system and obviously continue to gather the data. Melissa Lavasani: Um, Bergman's Bill emerging, uh, expanding veteran access to emerging treatments. Um, not only mandates the research, it gives the VA authority for this, uh, for running trials and, and creating programs around psychedelic medicines. But also, [00:10:00] one of the great things about it, I think, is it provides an on-ramp for veterans that don't necessarily qualify for clinical trials. Melissa Lavasani: You know, I think that's one of the biggest criticisms of clinical trials is like you're cre you're creating a vacuum for people and people don't live in a vacuum. So we don't necessarily know what psychedelics are gonna look like in real life. Um, but with this expanding veteran access bill that Bergman introduced, it provides the VA an opportunity to provide this access under. Melissa Lavasani: Um, in a, in a safe container with medical supervision while collecting data, um, while ensuring that the veteran that is going through this process has the support systems that it needs. So, um, you know, I think that there's a really unique opportunity here, and like Latrell said, like, we've got one shot at this. Melissa Lavasani: We have people's attention in Congress. Um, now's the time to start acting, and let's be really considerate and thoughtful about what we're doing with it. Joe Moore: Thanks for that, Melissa and Jay, how, [00:11:00] anything to add there on kind of your takeaways from the this, uh, last visit in dc? Jay Kopelman: Yeah, I, I think that Melissa highlighted it really well and there, there were a couple other things that I, I think, you know, you could kind of tie it all together with some other issues that we face in this country, uh, and that. Jay Kopelman: Uh, representative Correa brought up as well, but one of the things I wanted to go back and say is that veterans have kind of led this movement already, right? So, so it's a, it's a good jumping off point, right? That it's something people from both sides of the aisle, from any community in America can get behind. Jay Kopelman: You know, if you think about it, uh, in World War ii, you know, we had a million people serving our population was like, not even 200 million, but now [00:12:00] we have a population of 330 million, and at any given time there might be a million people in uniform, including the Reserve and the National Guard. So it's, it, it's an easy thing to get behind this small part of the population that is willing to sign that contract. Jay Kopelman: Where you are saying, yeah, I'm going to defend my country, possibly at the risk of my l my own life. So that's the first thing. The other thing is that the VA being a closed health system, and they don't have shareholders to answer to, they can take some risks, they can be innovative and be forward thinking in the ways that some other healthcare systems can't. Jay Kopelman: And so they have a perfect opportunity to show that they truly care for their veterans, which don't, I'm not saying they don't, but this would be an [00:13:00] opportunity to show that carrot at a whole different level. Uh, it would allow them to innovate and be a leader in something as, uh, as our friend Jim Hancock will say, you know. Jay Kopelman: When he went to the Naval Academy, they had the world's best shipbuilding program. Why doesn't the VA have the world's best care program for things like TBI and PTSD, which affects, you know, 40 something percent of all veterans, right? So, so there's, there's an opportunity here for the VA to lead from the front. Jay Kopelman: Um, the, these medicines provide, you know, reasonably lasting care where it's kind of a one and done. Whereas with the current systems, the, you know, and, and [00:14:00] again, not to denigrate the VA in any way, they're doing the best job they can with the tools in their toolbox, right? But maybe it's time for a trip to Home Depot. Jay Kopelman: Let's get some new tools. And have some new ways of fixing what's broken, which is really the way of doing things. It's not, veterans aren't broken, we are who we are. Um, but it's a, it's a way to fix what isn't working. So I, I think that, you know, given there's tremendous veteran homelessness still, you know, addiction issues, all these things that do translate to the population at large are things that can be worked on in this one system, the va that can then be shown to have efficacy, have good data, have [00:15:00] good outcomes, and, and take it to the population at large. Joe Moore: Mm-hmm. Brilliant. Thanks for that. And so there was another thing I wanted to pivot to, which is some of the recent press. So we've, um, seen a little bit of press around some, um, in one instance, some bad behavior in Mexico that a FI put out Americans thrive again, put out. And then another case there was a, a recent fatality. Joe Moore: And I think, um, both are tragic. Like we shouldn't be having to deal with this at this point. Um, but there's a lot of things that got us here. Um, it's not necessarily the operator's fault entirely, um, or even at all, honestly, like some medical interventions just carry a lot of risk. Like think, think about like, uh, how risky bypass surgery was in the nineties, right? Joe Moore: Like people were dying a lot from medical interventions and um, you know, this is a major intervention, uh, ibogaine [00:16:00] and also a lot of promise. To help people quite a bit. Um, but as of right now, there's, there's risk. And part of that risk, in my opinion, comes from the inability of organizations to necessarily collaborate. Joe Moore: Like there's no kind of convening body, sitting in the middle, allowing, um, for, and facilitating really good data sharing and learnings. Um, and I don't, I don't necessarily see an organization stepping up and being the, um, the convener for that kind of work. I've heard rumors that something's gonna happen there, and I'm, I'm hopeful I'll always wanna share my opinion on that. Joe Moore: But yeah. I don't know. Jay, from your perspective, is there anything you want to kind of speak to about, uh, these two recent incidents that Americans for Iboga kind of publicized recently? Jay Kopelman: Yeah, so I, I'll echo your sentiment, of course, that these are tragic incidents. Um, and I, [00:17:00] I think that at least in the case of the death at Ambio, AMBIO has done a very good job of talking about it, right? Jay Kopelman: They've been very honest with the information that they have. And like you said, there are risks inherent to these medicines, and it's like anything else in medicine, there are going to be risks. You know, when I went through, uh, when I, when I went through chemo, you know, there were, there are risks. You know, you don't feel well, you get sick. Jay Kopelman: Um, and, and it. There are processes in place to counter that when it happens. And there are processes and, and procedures and safety protocols in place when caring for somebody going through an ibogaine [00:18:00] journey. Uh, when I did it, we had EKG echocardiogram. You're on a heart monitor the entire time they push magnesium via iv. Jay Kopelman: You have to provide a urinalysis sample to make sure that there is nothing in your system that is going to potentially harm you. During the ibogaine, they have, uh, a cardiologist who is monitoring the heart monitors throughout the ibogaine experience. So the, the safety protocols are there. I think it's, I think it's just a matter of. Jay Kopelman: Standardizing them across all, all providers, right? Like, that would be a good thing if people would talk to one another. Um, as, as in any system, right? You've gotta have [00:19:00] some collaboration. You've gotta have standardization, you know, so, you know, they're not called standard operating procedures for nothing. Jay Kopelman: That means that in a, you know, in a given environment, everybody does things the same way. It's true in Navy and Marine Corps, air Force, army Aviation, they have standard operating procedures for every single aircraft. So if you fly, let's say the F 35 now, right? Because it's flown by the Navy, the Marine Corps, and the Air Force. Jay Kopelman: The, the emergency procedures in that airplane are standardized across all three services, so you should have the same, or, you know, with within a couple of different words, the same procedures and processes [00:20:00] across all the providers, right? Like maybe in one document you're gonna change, happy to glad and small dog to puppy, but it's still pretty much the, the same thing. Jay Kopelman: And as a service that provides scholarships to people to go access these medicines and go to these retreats, you know, my criteria is that the, this provider has to be safe. Number one, safety's paramount. It's always gotta be very safe. It should, it has to be effective. And you know, once you have those two things in place, then I have a comfort level saying, okay, yeah, we'll work with this provider. Jay Kopelman: But until those standardized processes are in place, you'll probably see these one-off things. I mean, some providers have been doing this longer than others and have [00:21:00] really figured out, you know, they've, they've cracked the code and, you know, sharing that across the spectrum would be good. Um, but just when these things happen, having a clearing house, right, where everybody can come together and talk about it, you know, like once the facts are known because. Jay Kopelman: To my knowledge, we still don't know all the facts. Like as, you know, as horrible as this is, you still have to talk about like an, has an autopsy been performed? What was found in the patient's system? You know, there, there are things there that we don't know. So we need to, we need to know that before we can start saying, okay, well this is how we can fix that, because we just don't know. Jay Kopelman: And, you know, to their credit, you know, Amio has always been safe to, to the, to the best of my knowledge. You know, I, [00:22:00] I haven't been to Ambio myself, but people that I have worked with have been there. They have observed, they have seen the process. They believe it's safe, and I trust their opinion because they've seen it elsewhere as well. Jay Kopelman: So yeah, having, having that one place where we can all come together when this happens, it, it's almost like it should be mandatory. In the military when there's a training accident, we, you know, we would have to have what's called a safety standout. And you don't do that again for a little while until you figure out, okay, how are we going to mitigate that happening again? Jay Kopelman: Believe me, you can go overboard and we don't want to do that. Like, we don't wanna just stop all care, but maybe stop detox for a week and then come back to it. [00:23:00] Joe Moore: Yeah. A dream would be, let's get like the, I don't know, 10, 20 most popular, uh, or well-known operators together somewhere and just do like a three day debrief. Joe Moore: Hey, everybody, like, here's what we see. Let's work on this together. You know how normal medicine works. And this is, it's hard because this is not necessarily, um, something people feel safe about in America talking about 'cause it's illicit here. Um, I don't understand necessarily how the operations, uh, relate to each other in Mexico, but I think that's something to like the public should dig into. Joe Moore: Like, what, what is this? And I, I'll start digging into that. Um, I, I asked a question recently of somebody like, is there some sort of like back channel signal everybody's using and there's no clear Yes. You know? Um, I think it would be good. That's just a [00:24:00] start, you know, that's like, okay, we can actually kind of say hi and watch out for this to each other. Jay Kopelman: It's not like we don't all know one another, right? Joe Moore: Yes. Jay Kopelman: Like at least three operators we're represented. At the Aspen Ibogaine meeting. So like that could be, and I think there was a panel kind of loosely related to this during Aspen Ibogaine meeting, but Joe Moore: mm-hmm. Jay Kopelman: It, you know, have a breakout where the operators can go sit down and kind of compare notes. Joe Moore: Right. Yeah. Melissa, do you have any, uh, comments on this thread here? And I, I put you on mute if you didn't see that. Um, Melissa Lavasani: all right, I'm off mute. Um, yeah, I think that Jay's hits the nail on the head with the collaboration thing. Um, I think that it's just a [00:25:00] problem across the entire ecosystem, and I think that's just a product of us being relatively new and upcoming field. Melissa Lavasani: Um, uh, it's a product of, you know. Our fundraising community is really small, so organizations feel like they are competing for the same dollars, even though their, their goals are all the same, they have different functions. Um, I think with time, I mean, let's be honest, like if we don't start collaborating and, and the federal government's moving forward, the federal government's gonna coordinate for us. Melissa Lavasani: And not, that might not necessarily be a bad thing, but, you know, we understand this issue to a whole other level that the federal government doesn't, and they're not required to understand it deeply. They just need to know how to really move forward with it the proper way. Um, but I think that it. It's really essential [00:26:00] that we all have this come together moment here so we can avoid things. Melissa Lavasani: Uh, I mean, no one's gonna die from bad advocacy. So like I've, I have a bit of an easier job. Um, but it can a, a absolutely stall efforts, um, to move things forward in Washington DC when, um, one group is saying one thing, another group is saying another thing, like, we're not quite at a point yet where we can have multiple lines of conversation and multiple things moving forward. Melissa Lavasani: Um, you know, for PMC, it's like, just let's get the first thing across the finish line. And we think that is, um, veteran healthcare. And, um, I know there's plenty of other groups out there that, that want the same thing. So, you know, I always, the reason why I put on the Federal Summit last year was I kind of hit my breaking point with a lack of collaboration and I wanted to just bring everyone in the same room and say like, all right, here are the things that we need to talk about. Melissa Lavasani: And I think the goal for this year is, um. To bring people in the same room and say, we talked about [00:27:00] we scratched the surface last year and this is where we need to really put our efforts into. And this is where the opportunities are. Um, I think that is going to, that's going to show the federal government if we can organize ourselves, that they need to take this issue really seriously. Melissa Lavasani: Um, I don't think we've done a great job at that thus far, but I think there's still plenty of time for us to get it together. Um, and I'm hoping with these two, uh, VA bills that are in the house right now and Senate is, is putting together their version of these two bills, um, so that they can move in tandem with each other. Melissa Lavasani: I think that, you know, there's an opportunity here for. Us to show the federal government as an ecosystem, Hey, we, we are so much further ahead and you know, this is what we've organized and here's how we can help you, um, that would make them buy into this issue a bit more and potentially move things forward faster. Melissa Lavasani: Uh, at this point in time, it's, I think that, [00:28:00] you know, psychedelics aren't necessarily the taboo thing that they, they used to be, but there's certainly places that need attention. Um, there's certainly conversations that need to be had, and like I said, like PMC is just one organization that can do this. Um, we can certainly organize and drive forward collaboration, but I, like we alone, cannot cover all this ground and we need the subject matter experts to collaborate with us so we can, you know, once we get in the door, we wanna bring the experts in to talk to these officials about it. Melissa Lavasani: So I. I, I really want listeners to really think about us as a convener of sorts when it comes to federal policy. Um, and you know, I think when, like for example, in the early eighties, a lot of people have made comparisons to the issue of psychedelics to the issue of AIDS research and how you have in a subject matter that's like extremely taboo and a patient population that the government [00:29:00] quite honestly didn't really care about in the early eighties. Melissa Lavasani: But what they did as an ecosystem is really organized themselves, get very clear on what they wanted the federal government to do. And within a matter of a couple years, uh, AIDS research funding was a thing that was happening. And what that, what that did was that ripple effect turned that into basically finding new therapies for something that we thought was a death, death sentence before. Melissa Lavasani: So I think. We just need to look at things in the past that have been really successful, um, and, and try to take the lessons from all of these issues and, and move forward with psychedelics. Joe Moore: Love that. And yes, we always need to be figuring out efficient approaches and where it has been successful in the past is often, um, an opportunity to mimic and, and potentially improve on that. Melissa Lavasani: Yeah. Jay Kopelman: One, one thing I think it's important to add to this part of the conversation is that, [00:30:00] you know, Melissa pointed out there are a number of organizations that are essentially doing the same thing. Jay Kopelman: Um, you know, I like to think we do things a little bit differently at Mission within Foundation in that we don't target any one specific type of service member. We, we work with all veterans. We work with first responders, but. What that leads to is that there are, as far as I've seen, nothing but good intentioned people in this space. Jay Kopelman: You know, people who really care about their patient population, they care about healing, they are trying to do a good job, and more importantly, they're trying to do good. Right? It, it, I think they all see the benefit down the road that this has, [00:31:00] pardon me, not just for veterans, but for society as a whole. Jay Kopelman: And, and ultimately that's where I would like to see this go. You know, I, I would love to see the VA take this. Take up this mantle and, and run with it and provide great data, great outcomes. You know, we are doing some data collection ourselves at Mission within foundation, albeit anecdotal based on surveys given before and after retreats. Jay Kopelman: But we're also working with, uh, Greg Fonzo down at UT Austin on a brain study he's doing that will have 40 patients in it when it's all said and done. And I think we have two more guys to put through that. Uh, and then we'll hit the 40. So there, there's a lot of good here that's being done by some really, really good people who've been doing this for a long time [00:32:00] and want to want nothing more than to, to see this. Jay Kopelman: Come to, come full circle so that we can take care of many, many, many people. Um, you know, like I say, I, I wanna work myself out of a job here. I, I just, I would love to see this happen and then I, you know, I don't have to send guys to Mexico to do this. They can go to their local VA and get the care that they need. Jay Kopelman: Um, but one thing that I don't think we've touched on yet, or regarding that is that the VA isn't designed for that. So it's gonna be a pretty big lift to get the right types of providers into the va with the knowledge, right, with the institutional knowledge of how this should be done, what is safe, what is effective, um, and then it, it's not just providing these medicines to [00:33:00] people and sending them home. Jay Kopelman: You don't just do that, you've gotta have the right therapists on the backend who can provide the integration coaching to the folks who are receiving these medicines. And I'm not just talking, I bga, even with MDMA and psilocybin, you should have a proper period of integration. It helps you to understand how this is going to affect you, what it, what the experience really meant, you know, because it's very difficult sometimes to just interpret it on your own. Jay Kopelman: And so what the experience was and what it meant to you. And, and so it will take some time to spin all that up. But once it's, once it's in place, you know, the sky's the limit. I think. Joe Moore: Kinda curious Jay, about what's, what's going on with Ibogaine at the federal level. Is there anything at VA right now? [00:34:00] Jay Kopelman: At the va? No, not with ibogaine. And, you know, uh, we, we send people specifically for IBOGAINE and five MEO, right? And, and so that, that doesn't preclude my interest in seeing this legislation passed, right? Jay Kopelman: Because it, it will start with something like MDMA or psilocybin, but ultimately it could grow to iboga, right? It the think about the cost savings at, at the va, even with psilocybin, right? Where you could potentially treat somebody with a very inexpensive dose of psilocybin or, or iboga one time, and then you, you don't have to treat them again. Jay Kopelman: Now, if I were, uh, you know, a VA therapist who's not trained in psychedelic trauma therapy. I might be worried [00:35:00] about job security, but it's like with anything, right? Like ultimately it will open pathways for new people to get that training or the existing people to get that training and, and stay on and do that work. Jay Kopelman: Um, which only adds another arrow to their quiver as far as I'm concerned, because this is coming and we're gonna need the people. It's just like ai, right? Like ai, yeah. Some people are gonna lose some jobs initially, and that's unfortunate. But productivity ultimately across all industries will increase and new jobs will be created as a result of that. Jay Kopelman: I mean, I was watching Squawk Box one morning. They were talking about the AI revolution and how there's gonna be a need for 500,000 electricians to. Build these systems that are going to work with the AI [00:36:00] supercomputers and, and so, Joe Moore: mm-hmm. Jay Kopelman: Where, where an opportunity may be lost. I think several more can be gained going forward. Melissa Lavasani: And just to add on what Jay just said there, there's nothing specific going on with Ibogaine at, at the va, but I think this administration is, is taking a real look at addiction in particular. Uh, they just launched, uh, a new initiative, uh, that's really centered on addiction treatments called the Great American Recovery. Melissa Lavasani: And, um, they're dedicating a hundred million dollars towards treating addiction as like a chronic treatable disease and not necessarily a law enforcement issue. So, um, in that initiative there will be federal grant programs for prevention and treatment and recovery. And, um, while this isn't just for psychedelic medicines, uh, I think it's a really great opportunity for the discussion of psychedelics to get elevated to the White House. Melissa Lavasani: Um, [00:37:00] there's also, previous to this announcement last week from the White House, there's been a hundred million dollars that was dedicated at, um, at ARPA h, which is. The advanced research projects, uh, agency for healthcare, um, and that is kind of an agency that's really focused on forward looking, um, treatments and technologies, uh, for, um, a, a whole slew of. Melissa Lavasani: Of issues, but this a hundred million dollars is dedicated to mental health and addiction. So there's a lot of opportunity there as well. So we, while I think, you know, some people are talking about, oh, we need a executive order on Iboga, it's like, well, you know, the, the president is thinking, um, about, you know, what issues can land with his, uh, voting block. Melissa Lavasani: And I think it's, I don't think we necessarily need a specific executive order on Iboga to call this a success. It's like, let's look at what, [00:38:00] um, what's just been announced from the White House. They're, they're all in on. Thinking creatively and finding, uh, new solutions for this. And this is kind of, this aligns with, um, HHS secretaries, uh, Robert F. Melissa Lavasani: Kennedy Junior's goals when he took on this, this role of Health Secretary. Um, addiction has been a discussion that, you know, he has personal, um, a personal tie to from his own experience. And, um, I think when this administration started, there was so much like fervor around the, the dialogue of like, everyone's talking about psychedelics. Melissa Lavasani: It was Secretary Kennedy, it was, uh, secretary Collins at the va. It was FDA Commissioner Marty Macari. And I think that there's like a lot of undue frustration within folks 'cause um, you don't necessarily snap your fingers and change happens in Washington dc This is not the city for that. And it's intentionally designed to move slow so that we can avoid really big mistakes. Melissa Lavasani: Um. [00:39:00] I think we're a year into this administration and these two announcements are, are pretty huge considering, um, you know, the, we, there are known people within domestic policy council that don't, aren't necessarily supportive of psychedelic medicine. So there's a really amazing progress here, and frustrating as it might be to, um, just be waiting for this administration to make some major move. Melissa Lavasani: I think they are making major moves like for Washington, DC These, these are major moves and we just gotta figure out how we can, um, take these initiatives and apply them to the issue of psychedelic medicines. Joe Moore: Thanks, Melissa. Um, yeah, it is, it is interesting like the amount of fervor there was at the beginning. You know, we had, uh. Kind of one of my old lawyers, Matt Zorn, jumped in with the administration. Right. And, um, you know, it was, uh, really cool to [00:40:00] see and hopeful how much energy was going on. It's been a little quiet, kind of feels like a black box a little bit, but I, you know, there was, Melissa Lavasani: that's on me. Melissa Lavasani: Maybe I, we need to be more out in public about like, what's actually happening, because I feel like, like day in and day out, it's just been, you gotta just mm-hmm. Like have that constant beat with the government. Mm-hmm. And, um, it's, it's, it's not the photo ops on the hill, it's the conversations that you have. Melissa Lavasani: It's the dinner parties you go to, it's the fundraisers you attend, you know? Mm-hmm. That's why I, I kind of have to like toot my own horn with PCs. Like, we need to be present here at, at not only on the Hill, not only at the White House, but kind of in the ecosystem of Washington DC itself. There's, it's, there are like power players here. Melissa Lavasani: There are people that are connected that can get things done, like. I mean, the other last week we had a big snow storm. I walked over to my friend's house, um, to have like a little fire sesh with them and our kids, and his next door neighbor came over. He was a member of Congress. I talked about the VA bills, like [00:41:00] we're reaching out to his office now, um, to get them, um, up to speed and hopefully get their co-sponsorship for, uh, the two VA bills. Melissa Lavasani: So, I mean, it, the little conversations you have here are just as important as the big ones with the photo ops. So, um, it, it's, it's really like, you know, building up that momentum and, and finding that time where you can really strike and make something happen. Joe Moore: Mm-hmm. Yeah. Jay, anything to add there? Jay Kopelman: Yeah, I was just gonna say that, you know, I, I, I think the fervor is still there, right? Jay Kopelman: But real life happens. Melissa Lavasani: Yes, Jay Kopelman: yes. And gets in the way, right? So, Melissa Lavasani: yeah, Jay Kopelman: I, I can't imagine how many issues. Secretary Kennedy has every day much less the president. Like there's so many things that they are dealing with on a daily basis, right? It, we, we just have to work to be the squeaky wheel in, in the right way, right. Jay Kopelman: [00:42:00] With the, with the right information at the right time. Like just inundating one of these organizations with noise, it's then it be with Informa, it just becomes noise, right? It it, it doesn't help. So when we have things to say that are meaningful and impactful, we do, and Melissa does an amazing job of that. Jay Kopelman: But, you know, it, it takes time. You know, it's, you know, we're not, this is, this is like turning an aircraft carrier, not a ski boat. Melissa Lavasani: Yeah, Joe Moore: yeah, absolutely. Um, and. It's, it's understandably frustrating, I think for the public and the psychedelic public in particular because we see all this hope, you know, we continue to get frustrated at politics. It's nothing new, right? Um, and we, we wanna see more people get well immediately. [00:43:00] And I, I kind of, Jay from the veteran perspective, I do love the kind of loud voices like, you're making me go to Mexico for this. Joe Moore: I did that and you're making me leave the country for the thing that's gonna fix me. Like, no way. And barely a recognition that this is a valid treatment. You know, like, you know, that is complicated given how medicine is structured here domestically. But it's also, let's face the facts, like the drug war kind of prevented us from being able to do this research in the first place. Joe Moore: You know? Thanks Nixon. And like, how do we actually kind of correct course and say like, we need to spend appropriately on science here so we can heal our own people, including veterans and everybody really. It's a, it's a dire situation out there. Jay Kopelman: Yeah. It, it really is. Um, you know, we were talking briefly about addicts, right? Jay Kopelman: And you know, it's not sexy. People think of addicts as people who are weak-minded, [00:44:00] right? They don't have any self-control. Um, but, but look at, look at the opioid crisis, right? That Brian Hubbard was fighting against in Kentucky for all those years. That that was something that was given to the patient by a doctor that they then became dependent on, and a lot of people died from that. Jay Kopelman: And, and so you, you know, it's, I I don't think it's fair to just put all addicts in a box. Just like it's not fair to put all veterans in a box. Just like it's not fair for doctors, put all their patients in a box. We're individuals. We, we have individual needs. Our, our health is very individual. Like, I, I don't think I should be put in the same box as every other 66-year-old that my doctor sees. Jay Kopelman: It's not fair. [00:45:00] You know, if you, if you took my high school classmates and put us all in a photo, we're all gonna have different needs, right? Like, some look like they're 76, not 66. Some look like they're 56. Not like they're, we, we do things differently. We live our lives differently. And the same is true of addicts. Jay Kopelman: They come to addiction from different places. Not everybody decides they want to just try heroin at a party, and all of a sudden they're addicted. It happens in, in different ways, you know, and the whole fentanyl thing has been so daggum nefarious, right? You know, pushing fentanyl into marijuana. Jay Kopelman: Somebody's smoking a joint and all of a sudden they're addicted to fentanyl or they die. Melissa Lavasani: I think we're having a, Jay Kopelman: it's, it's just not fair to, to say everybody in this pot is the same, or everybody in this one is the same. We have [00:46:00] to look at it differently. Joe Moore: Yeah. I like to zoom one level out and kind of talk about, um, just how hurt we are as a country, as a world really, but as a country specifically, and how many people are out of work for so many. Joe Moore: Difficult reasons and away from their families for so many kind of tragic reasons. And if we can get people back to their families and back to work, a lot of these things start to self-correct, but we have to like have those interventions where we can heal folks and, and get them back. Um, yeah. And you know, everything from trauma, uh, in childhood, you know, adulthood, combat, whatever it is. Joe Moore: Like these things can put people on the sidelines. And Jay, to your point, like you get knee surgery and all of a sudden you're, you know, two years later you're on the hunt for Fentanyl daily. You know, that's tough. It's really tough. Carl Hart does a good job talking about this kind of addiction pipeline and [00:47:00] a few others do as well. Joe Moore: But it's just, you know, kind of putting it in a moral failure bucket. It's not great. I was chatting with somebody about, um, veterans, it's like you come back and you're like, what's gonna make me feel okay right now? And it's not always alcohol. Um, like this is the first thing that made me feel okay, because there's not great treatments and there's, there's a lot of improvements in this kind of like bringing people back from the field that needs to happen. Joe Moore: In my opinion. I, it seems to be shared by a lot of people, but yeah, there's, it's, it's, IGA is gonna be great. It's gonna be really important. I really can't wait for it to be at scale appropriately, but there's a lot of other things we need to fix too, um, so that we can just, you know, not have so many people we need to, you know, spend so much money healing. Joe Moore: Mm-hmm. Jay Kopelman: Yeah. You ahead with that. We don't need the president to sign an executive order to automatically legalize Ibogaine. Right. But it would be nice if he would reschedule it so that [00:48:00] then then researchers could do this research on a larger scale. You know, we could, we could now get some real data that would show the efficacy. Jay Kopelman: And it could be done in a safe environment, you know? And, and so that would be, do Joe Moore: you have any kind of figures, like, like, I've been talking about this for a while, Jay. Like, does it drop the cost a lot of doing research when we deschedule things? Jay Kopelman: I, I would imagine so, because it'll drop the cost of accessing the medicines that are being researched. Jay Kopelman: Right? You, you would have buy-in from more organizations. You know, you might even have a pharma company that comes into this, you know, look at j and j with the ketamine, right? They have, they have a nasal spray version of ketamine that's doing very well. I mean, it's probably their, their biggest revenue [00:49:00] provider for them right now. Jay Kopelman: And, and so. You know, you, it would certainly help and I think, I think it would lower costs of research to have something rescheduled rather than being schedule one. You know it, people are afraid to take chances when you're talking about Schedule one Melissa Lavasani: labs or they just don't have the money to research things that are on Schedule one. Melissa Lavasani: 'cause there's so much in an incredible amount of red tape that you have to go through and, and your facility has to be a certain way and how you contain those, uh, medicines. Oh, researching has to be in a specific container and it's just very cumbersome to research schedule one drugs. So absolutely the cost would go down. Melissa Lavasani: Um, but Joe Moore: yeah, absolutely. Less safes. Melissa Lavasani: Yeah. Joe Moore: Yes. Less uh, Melissa Lavasani: right. Joe Moore: Locked. Yeah. Um, it'll be really interesting when that happens. I'm gonna hold out faith. That we can see some [00:50:00] movement here. Um, because yeah, like why make healing more expensive than it needs to be? I think like that's potentially a protectionist move. Joe Moore: Like, I'm not, I'm not here yet, but, um, look at AbbVie's, uh, acquisition of the Gilgamesh ip. Mm-hmm. Like that's a really interesting move. I think it was $1.2 billion. Mm-hmm. So they're gonna wanna protect that investment. Um, and it's likely going to be an approved medication. Like, I don't, I don't see a world in which it's not an approved medication. Joe Moore: Um, you know, I don't know a timeline, I would say Jay Kopelman: yeah. Joe Moore: Less than six years, just given how much cash they've got. But who knows, like, I haven't followed it too closely. So, and that's an I bga derivative to be clear, everybody, um mm-hmm. If you're not, um, in, in the loop on that, which is hopeful, you know? Joe Moore: Mm-hmm. But I don't know what the efficacy is gonna be with that compared to Ibogaine and then we have to talk about the kind of proprietary molecule stuff. Um, there's like a whole bunch of things that are gonna go on here, and this is one of the reasons why I'm excited about. Federal involvement [00:51:00] because we might actually be able to have some sort of centralized manufacturer, um, or at least the VA could license three or four generic manufacturers per for instance, and that way prices aren't gonna be, you know, eight grand a dose or whatever. Joe Moore: You know, it's, Jay Kopelman: well, I think it's a very exciting time in the space. You know, I, I think that there's the opportunity for innovation. There is the opportunity for collaboration. There's the opportunity for, you know, long-term healing at a very low cost. You know, that we, we have the highest healthcare cost per capita in the world right here in the us. Jay Kopelman: And, and yet we are not the number one health system in the world. So to me, that doesn't add up. So we need to figure out a way to start. Bringing costs down for a lot of people and [00:52:00] at the same time increasing, increasing outcomes. Joe Moore: Absolutely. Yeah. There's a lot of possible outcome improvements here and, and you know, everything from relapse rates, like we hear often about people leaving a clinic and they go and overdose when they get home. Tragically, too common. I think there's everything from, you know, I'm Jay, I'm involved in an organization called the Psychedelics and Pain Association. Joe Moore: We look at chronic pain very seriously, and IGA is something we are really interested in. And if. We could have better, you know, research, there better outcome measures there. Um, you know, perhaps we can have less people on opioids to begin with from chronic pain conditions. Um, Jay Kopelman: yeah, I, I might be due for another Ibogaine journey then, because I deal with chronic pain from Jiujitsu, but, Joe Moore: oh gosh, let's Jay Kopelman: talk Joe Moore: later. Jay Kopelman: That's self inflicted. Some people would say take a month off, but Melissa Lavasani: yeah, Jay Kopelman: I'm [00:53:00] not, I'm not that smart. Joe Moore: Yeah. Um, but you know, this, uh, yeah, this whole thing is gonna be really interesting to see how it plays out. I'm endlessly hopeful pull because I'm still here. Right. I, I've been at this for almost 10 years now, very publicly, and I think we are seeing a lot of movement. Joe Moore: It's not always what we actually wanna see, but it is movement nonetheless. You know, how many people are writing on this now than there were before? Right. You know, we, we have people in New York Times writing somewhat regularly about psychedelics and. Even international media is covering it. What do we have legalization in Australia somewhat recently for psilocybin and MDMA, Czech Republic. Joe Moore: I think Germany made some moves recently. Mm-hmm. Um, really interesting to see how this is gonna just keep shifting. Um Jay Kopelman: mm-hmm. Joe Moore: And I think there's no way that we're not gonna have prescription psychedelics in three years in the United States. It pro probably more like a [00:54:00] year and a half. I don't know. Do you, are you all taking odds? Melissa Lavasani: Yeah. I mean, I think Jay Kopelman: I, I gotta check Cal sheet, see what they're saying. Melissa Lavasani: I think it's safe to say, I mean, this could even come potentially the end of this year, I think, but definitely by the end of 2027, there's gonna be at least one psychedelic that's FDA approved. Joe Moore: Yeah. Yeah. Melissa Lavasani: If you're not counting Ketamine. Joe Moore: Right. Jay Kopelman: I, I mean, I mean it mm-hmm. It, it doesn't make sense that it. Shouldn't be or wouldn't be. Right. The, we've seen the benefits. Mm-hmm. We know what they are. It's at a very low cost, but you have to keep in mind that these things, they need to be done with the right set setting and container. Right. And, and gotta be able to provide that environment. Jay Kopelman: So, but I would, I would love, like I said, I'd love to work myself out of a job here and see this happen, not just for our veterans, [00:55:00] but for everybody. Joe Moore: Mm-hmm. Um, so Melissa, is there a way people can get involved or follow PMC or how can they support your work at PMC? Melissa Lavasani: Yeah, I mean, follow us in social media. Melissa Lavasani: Um, our two biggest platforms are LinkedIn and Instagram. Um, I'm bringing my newsletter back because I'm realizing, um, you know, there is a big gap in, in kind of like the knowledge of Washington DC just in general. What's happening here, and I think, you know, part of PC's value is that we're, we are plugged into conversations that are being had, um, here in the city. Melissa Lavasani: And, you know, we do get a little insight. Um, and I think that that would really quiet a lot of, you know, the, a lot of noise that, um, exists in the, our ecosystem. If, if people just had some clarity on like, what's actually happening or happening here and what are the opportunities and, [00:56:00] um, where do we need more reinforcement? Melissa Lavasani: Um, and, and also, you know, as we're putting together public education campaign, you know. My, like, if I could get everything I wanted like that, that campaign would be this like multi-stakeholder collaborative effort, right? Where we're covering all the ground that we need to cover. We're talking to the patient groups, we're talking to traditional mental health organizations, we're talking to the medical community, we're talking to the general population. Melissa Lavasani: I think that's like another area that we, we just seem to be, um, lacking some effort in. And, you know, ultimately the veteran story's always super compelling. It pulls on your heartstrings. These are our heroes, um, of our country. Like that, that is, that is meaningful. But a lot of the veteran population is small and we need the, like a, the just.[00:57:00] Melissa Lavasani: Basic American living in middle America, um, understanding what psychedelics are so that in, in, in presenting to them the stories that they can relate to, um, because that's how you activate the public and you activate the public and you get them to see what's happening in these clinical trials, what the data's been saying, what the opportunities are with psychedelics, and then they start calling their members of Congress and saying, Hey, there is this. Melissa Lavasani: Bill sitting in Congress and why haven't you signed onto it? And that political pressure, uh, when used the right way can be really powerful. So, um, I think, you know, now we're at this really amazing moment where we have a good amount of congressional offices that are familiar enough with psychedelics that they're willing to move on it. Melissa Lavasani: Um, there's another larger group, uh, that is familiar with psychedelics and will assist and co-sponsor legislation, but there's still so many offices that we haven't been able to get to just 'cause like we don't have all the time in the world and all the manpower in the world to [00:58:00] do it. But, you know, that is one avenue is like the advocates can speak to the, the lawmakers, the experts speak to the lawmakers, and we not, we want the public engaged in this, you know, ultimately, like that's. Melissa Lavasani: Like the best form of harm reduction is having an informed public. So we are not, they're not seeing these media headlines of like, oh, this miracle cure that, um, saved my family. It's like, yes, that can happen psychedelics. I mean, person speaking personally, psychedelics did save my family. But what you miss out of that story is the incredible amount of work I put into myself and put into my mental health to this day to maintain, um, like myself, my, my own agency and like be the parent that I wanna be and be the spouse that I wanna be. Melissa Lavasani: So, um, we, we need to continue to share these stories and we need to continue to collaborate to get this message out because we're all, we're all in the same boat right now. We all want the same things. We want patients to have safe and [00:59:00] affordable access to psychedelic assisted care. Um, and, uh. We're just in the beginning here, so, um, sign up for our newsletter and we can sign up on our website and then follow us on social media. Melissa Lavasani: And, um, I anticipate more and more events, um, happening with PMC and hopefully we can scale up some of these events to be much more public facing, um, as this issue grows. So, um, I'm really excited about the future and I'm, I've been enjoying this partnership with Mission Within. Jay is such a professional and, and it really shows up when he needs to show up and, um, I look forward to more of that in the future. Joe Moore: Fantastic. And Jay, how can people follow along and support mission within Foundation? Jay Kopelman: Yeah, again, social media is gonna be a good way to do that. So we, we are also pretty heavily engaged on LinkedIn and on Instagram. Um, I do [01:00:00] share, uh, a bit of my own stuff as well. On social media. So we have social media pages for Mission within Foundation, and we have a LinkedIn page for mission within foundation. Jay Kopelman: I have my own profiles on both of those as well where people can follow along. Um, one of the other things you know that would probably help get more attention for this is if the general public was more aware of the numbers of professional athletes who are also now pursuing. I began specifically to help treat their traumatic brain injuries and the chronic traumatic encephalopathy that they've, uh, suffered as a result of their time in professional sports or even college sports. Jay Kopelman: And, you know. I people worship these athletes, and I [01:01:00] think that if more of them, like Robert Gall, were more outspoken about these treatments and the healing properties that they've provided them, that it would get even more attention. Um, I think though what Melissa said, you know, I don't wanna parrot anything she just said because she said it perfectly Right. Jay Kopelman: And I'd just be speaking to hear myself talk. Um, but being collaborative the way that we are with PMC and with Melissa is I think, the way to move the needle on this overall. And like she said, if she could get more groups involved in, in these discussions, it would, it would do wonders for us. Joe Moore: Well, thank you both so much for your hard work out there. I always appreciate it when people are showing up and doing this important, [01:02:00] sometimes boring and tedious, but nevertheless sometimes, sometimes exciting work. And um, so yeah, just thank you both and thank you both for showing up here to psychedelics today to join us and I hope we can continue to support you all in the future. Jay Kopelman: Thank you, Joe. Thank you, Joe. It's a pleasure being with you today and with Melissa, of course, always Melissa Lavasani: appreciate the time and space. Joe Moore: Thanks.